CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | zwitterion |
|
Accession: | CHEBI:27369
|
browse the term
|
Definition: | A neutral compound having formal unit electrical charges of opposite sign on non-adjacent atoms. Sometimes referred to as inner salts, dipolar ions (a misnomer). |
Synonyms: | exact_synonym: | zwitterions |
| related_synonym: | compose zwitterionique; compuestos zwitterionicos; zwitteriones; zwitterionic compounds |
|
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
increases expression |
EXP |
Carnitine results in increased expression of ADIPOQ protein |
CTD |
PMID:30256492 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions increases phosphorylation |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Carnitine results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:29186614 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
Carnitine promotes the reaction [Paraquat deficiency inhibits the reaction [Paraquat promotes the reaction [APP protein binds to APP protein]]] |
CTD |
PMID:33290254 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
decreases expression multiple interactions |
EXP |
Carnitine results in decreased expression of BAX protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Carnitine results in decreased expression of BAX protein] |
CTD |
PMID:29186614 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bbox1 |
gamma-butyrobetaine hydroxylase 1 |
increases chemical synthesis multiple interactions |
ISO |
BBOX1 protein results in increased chemical synthesis of Carnitine Aluminum inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]; Hydrogen Peroxide inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]; Ketoglutaric Acids inhibits the reaction [Aluminum inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]]; Ketoglutaric Acids inhibits the reaction [Hydrogen Peroxide inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]] |
CTD |
PMID:21439360 |
|
NCBI chr 3:96,822,654...96,871,786
Ensembl chr 3:96,822,655...96,871,458
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions increases phosphorylation |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Carnitine results in increased phosphorylation of BCL2 protein]; Carnitine inhibits the reaction [Ifosfamide results in decreased expression of BCL2 mRNA] |
CTD |
PMID:23213347 PMID:29186614 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [Gentamicins results in decreased expression of BCL2L1 protein] |
CTD |
PMID:19491382 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP ISO |
Carnitine inhibits the reaction [Gentamicins results in increased cleavage of CASP3 protein]; Carnitine inhibits the reaction [Ifosfamide results in increased expression of CASP3 mRNA]; Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of CASP3 mRNA]] Carnitine inhibits the reaction [quinone results in increased activity of CASP3 protein] |
CTD |
PMID:19491382 PMID:23213347 PMID:26562095 PMID:32478940 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
Carnitine inhibits the reaction [quinone results in increased activity of CASP8 protein] |
CTD |
PMID:32478940 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP ISO |
Carnitine inhibits the reaction [Ifosfamide results in increased expression of CASP9 mRNA] Carnitine inhibits the reaction [quinone results in increased activity of CASP9 protein] |
CTD |
PMID:23213347 PMID:32478940 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
Carnitine inhibits the reaction [Diethylnitrosamine results in decreased activity of CAT protein]; Carnitine inhibits the reaction [Doxorubicin results in decreased activity of CAT protein]; Carnitine inhibits the reaction [Ifosfamide results in decreased expression of CAT mRNA] |
CTD |
PMID:16889571 PMID:19294768 PMID:23213347 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [Sunitinib results in increased expression of CCN2 mRNA] |
CTD |
PMID:26581635 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of CDH1 protein] |
CTD |
PMID:28973641 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
EXP |
Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of COL1A1 mRNA]; Carnitine inhibits the reaction [Sunitinib results in increased expression of COL1A1 mRNA] |
CTD |
PMID:26581635 PMID:28973641 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
multiple interactions |
EXP |
[COL2A1 protein co-treated with Freund's Adjuvant] affects the abundance of Carnitine; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Carnitine]; Dexamethasone inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Carnitine]; huang-lien-chieh-tu-tang inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Carnitine] |
CTD |
PMID:24709313 |
|
NCBI chr 7:129,098,489...129,127,620
Ensembl chr 7:129,098,786...129,127,546
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
ISO EXP |
[Doxorubicin co-treated with Carnitine] results in increased expression of CPT1A mRNA; [Genistein co-treated with Carnitine] results in increased expression of CPT1A protein; Carnitine inhibits the reaction [quinone results in decreased expression of CPT1A protein] valproyl-coenzyme A inhibits the reaction [CPT1A protein results in increased metabolism of Carnitine] |
CTD |
PMID:16283381 PMID:16362726 PMID:19854160 PMID:32478940 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Cpt2 |
carnitine palmitoyltransferase 2 |
multiple interactions |
ISO |
Carnitine promotes the reaction [[Bezafibrate results in increased activity of CPT2 protein] which results in increased abundance of Adenosine Triphosphate] |
CTD |
PMID:21816645 |
|
NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions |
EXP |
Carnitine inhibits the reaction [Sunitinib results in increased expression of CYBB mRNA]; Carnitine inhibits the reaction [Sunitinib results in increased expression of CYBB protein] |
CTD |
PMID:26581635 |
|
NCBI chr X:13,360,583...13,392,517
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [Atrazine results in decreased expression of CYP17A1 mRNA] |
CTD |
PMID:29710542 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP |
Carnitine promotes the reaction [Ethanol results in increased expression of CYP2E1 protein] |
CTD |
PMID:8130774 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Fabp3 |
fatty acid binding protein 3 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [Doxorubicin results in decreased expression of FABP3 mRNA] |
CTD |
PMID:20470772 |
|
NCBI chr 5:142,651,962...142,658,707
Ensembl chr 5:142,651,956...142,658,718
|
|
G |
Fabp9 |
fatty acid binding protein 9 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [carbendazim results in decreased expression of FABP9 mRNA]; Carnitine inhibits the reaction [carbendazim results in decreased expression of FABP9 protein] |
CTD |
PMID:33965443 |
|
NCBI chr 2:91,591,842...91,595,873
Ensembl chr 2:91,592,298...91,595,873
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
multiple interactions |
EXP |
Carnitine inhibits the reaction [carbendazim results in decreased expression of FSHB protein] |
CTD |
PMID:33965443 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [Ifosfamide results in decreased expression of GPX1 mRNA] |
CTD |
PMID:23213347 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Hadha |
hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha |
multiple interactions |
ISO |
Carnitine inhibits the reaction [quinone results in decreased expression of HADHA protein] |
CTD |
PMID:32478940 |
|
NCBI chr 6:26,187,969...26,227,605
Ensembl chr 6:26,187,956...26,227,869
|
|
G |
Hrk |
harakiri, BCL2 interacting protein |
multiple interactions |
ISO |
Carnitine inhibits the reaction [Gentamicins results in increased expression of HRK mRNA]; Carnitine inhibits the reaction [Gentamicins results in increased expression of HRK protein] |
CTD |
PMID:16239342 |
|
NCBI chr12:38,387,484...38,409,652
|
|
G |
Hspa2 |
heat shock protein family A (Hsp70) member 2 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [Cadmium Chloride results in increased expression of HSPA2 protein] |
CTD |
PMID:22359436 |
|
NCBI chr 6:95,128,504...95,131,281
Ensembl chr 6:95,128,350...95,131,287
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
increases abundance multiple interactions |
ISO |
IDH2 protein mutant form results in increased abundance of Carnitine Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Carnitine] |
CTD |
PMID:27469509 |
|
NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [carbendazim results in decreased expression of IL10 protein]; Carnitine inhibits the reaction [Sunitinib results in decreased expression of IL10 mRNA] |
CTD |
PMID:26581635 PMID:33965443 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of IL1B mRNA]]; Carnitine inhibits the reaction [sunitinib results in increased expression of IL1B mRNA] |
CTD |
PMID:26562095 PMID:26581635 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [carbendazim results in increased expression of IL6 protein]; Carnitine inhibits the reaction [Sunitinib results in increased expression of IL6 mRNA] |
CTD |
PMID:26581635 PMID:33965443 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Lepr |
leptin receptor |
affects abundance |
ISO |
LEPR affects the abundance of Carnitine |
CTD |
PMID:20567778 |
|
NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
|
|
G |
Lhb |
luteinizing hormone subunit beta |
multiple interactions |
EXP |
Carnitine inhibits the reaction [carbendazim results in decreased expression of LHB protein] |
CTD |
PMID:33965443 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [sunitinib results in decreased expression of MMP9 mRNA] |
CTD |
PMID:26581635 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions increases activity |
EXP |
[Carboplatin co-treated with Carnitine deficiency] results in increased expression of MPO protein; Acetaminophen promotes the reaction [Carnitine deficiency results in increased activity of MPO protein] |
CTD |
PMID:18597074 PMID:18852009 |
|
NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mt-co1 |
mitochondrially encoded cytochrome c oxidase I |
multiple interactions |
ISO |
Carnitine inhibits the reaction [nickel chloride results in decreased expression of COX1 mRNA] |
CTD |
PMID:21419151 |
|
NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867
|
|
G |
Mt-nd6 |
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6 |
multiple interactions |
ISO |
Carnitine inhibits the reaction [nickel chloride results in decreased expression of ND6 mRNA] |
CTD |
PMID:21419151 |
|
NCBI chr MT:13,543...14,061
Ensembl chr MT:13,543...14,061
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
multiple interactions |
EXP |
Carnitine inhibits the reaction [Stavudine results in decreased expression of MTTP mRNA] |
CTD |
PMID:18299183 |
|
NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [carbendazim results in increased expression of NOS2 protein]; Carnitine inhibits the reaction [Ifosfamide results in increased expression of NOS2 mRNA] |
CTD |
PMID:23213347 PMID:33965443 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
increases expression |
EXP |
Carnitine results in increased expression of NOS3 |
CTD |
PMID:20123095 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Ocln |
occludin |
multiple interactions |
EXP |
Carnitine inhibits the reaction [carbendazim results in decreased expression of OCLN protein] |
CTD |
PMID:33965443 |
|
NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
increases activity multiple interactions |
EXP |
Carnitine results in increased activity of PPARA protein [pirinixic acid results in increased activity of PPARA protein] promotes the reaction [SLC22A21 protein results in increased uptake of Carnitine]; PPARA protein promotes the reaction [Carnitine results in decreased susceptibility to Gentamicins] |
CTD |
PMID:19491382 PMID:19735737 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression multiple interactions |
EXP |
Carnitine results in increased expression of PPARG protein Carnitine inhibits the reaction [[Dietary Fats co-treated with Fructose] results in decreased expression of PPARG protein] |
CTD |
PMID:30256492 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ptgis |
prostaglandin I2 synthase |
increases response to substance multiple interactions increases expression |
EXP |
PTGIS protein results in increased susceptibility to Carnitine [Carnitine results in increased expression of PTGIS mRNA] which results in increased chemical synthesis of 6-Ketoprostaglandin F1 alpha |
CTD |
PMID:19491382 |
|
NCBI chr 3:155,928,564...155,964,228
Ensembl chr 3:155,916,412...155,965,451
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
Carnitine inhibits the reaction [carbendazim results in increased expression of RELA protein] |
CTD |
PMID:33965443 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Slc22a21 |
solute carrier family 22 (organic cation transporter), member 21 |
increases uptake multiple interactions |
EXP |
SLC22A21 protein results in increased uptake of Carnitine [pirinixic acid results in increased activity of PPARA protein] promotes the reaction [SLC22A21 protein results in increased uptake of Carnitine] |
CTD |
PMID:19735737 |
|
NCBI chr10:38,104,114...38,133,106
Ensembl chr10:38,104,122...38,130,671
|
|
G |
Slc22a4 |
solute carrier family 22 member 4 |
increases uptake |
ISO |
SLC22A4 protein results in increased uptake of Carnitine |
CTD |
PMID:21256917 |
|
NCBI chr10:38,133,333...38,179,932
Ensembl chr10:38,133,322...38,179,720
|
|
G |
Slc22a5 |
solute carrier family 22 member 5 |
multiple interactions decreases expression increases transport affects binding affects uptake increases expression increases uptake |
ISO EXP |
[Doxorubicin co-treated with Carnitine] results in increased expression of SLC22A5 mRNA; Amiodarone inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Atorvastatin inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Betaine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Carnitine inhibits the reaction [SLC22A5 protein results in increased transport of pivaloylcarnitine]; Choline inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Clozapine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; grepafloxacin affects the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Ipratropium inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Lidocaine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Nifedipine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Ofloxacin inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Olanzapine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine analog]; pivaloylcarnitine inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]; Propranolol inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Quetiapine Fumarate inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Spironolactone inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; talinolol inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; ziprasidone inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine] Carnitine results in decreased expression of SLC22A5 mRNA; Carnitine results in decreased expression of SLC22A5 protein Carnitine binds to SLC22A5 protein SLC22A5 protein affects the uptake of Carnitine 1-Methyl-4-phenylpyridinium inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of SLC22A5 mRNA]; Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of SLC22A5 protein]; Carnitine inhibits the reaction [Doxorubicin results in decreased expression of SLC22A5 mRNA]; Carnitine inhibits the reaction [SLC22A5 protein results in increased uptake of Tetraethylammonium]; Dithioerythritol inhibits the reaction [Omeprazole inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]]; Ofloxacin inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Omeprazole inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]; Tetraethylammonium inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine] Carnitine deficiency results in increased expression of SLC22A5 mRNA SLC22A5 protein results in increased uptake of Carnitine; SLC22A5 protein results in increased uptake of Carnitine analog |
CTD |
PMID:12644265 PMID:15486076 PMID:16283381 PMID:16928358 PMID:18762717 PMID:18981167 PMID:19041296 PMID:19539806 PMID:19735737 PMID:20303936 PMID:20470772 PMID:21256917 PMID:21641380 PMID:22701146 PMID:30465787 PMID:31437515 More...
|
|
NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309
|
|
G |
Slc22a8 |
solute carrier family 22 member 8 |
increases transport |
ISO |
SLC22A8 protein results in increased transport of Carnitine |
CTD |
PMID:15100168 |
|
NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450
|
|
G |
Slc25a20 |
solute carrier family 25 member 20 |
multiple interactions increases transport |
EXP |
Ampicillin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]; Carnitine inhibits the reaction [Hydrogen Peroxide results in decreased activity of SLC25A20 protein]; Cefazolin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]; Cefonicid inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]; Cephalothin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]; Piperacillin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine] |
CTD |
PMID:18452908 PMID:23402788 |
|
NCBI chr 8:109,365,056...109,386,512
Ensembl chr 8:109,365,002...109,386,512
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions increases expression |
EXP |
Carnitine inhibits the reaction [[Dietary Fats co-treated with Fructose] results in decreased expression of SLC2A4 protein] Carnitine results in increased expression of SLC2A4 protein |
CTD |
PMID:30256492 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Snai1 |
snail family transcriptional repressor 1 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of SNAI1 protein] |
CTD |
PMID:28973641 |
|
NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [Stavudine results in increased expression of SREBF1 mRNA] |
CTD |
PMID:18299183 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions |
EXP |
Carnitine inhibits the reaction [carbendazim results in decreased expression of STAR mRNA]; Carnitine inhibits the reaction [carbendazim results in decreased expression of STAR protein] |
CTD |
PMID:33965443 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of TGFB1 mRNA]]; Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of TGFB1 mRNA]; Carnitine inhibits the reaction [sunitinib results in increased expression of TGFB1 mRNA] |
CTD |
PMID:26562095 PMID:26581635 PMID:28973641 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [sunitinib results in increased expression of TIMP1 mRNA] |
CTD |
PMID:26581635 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tjp1 |
tight junction protein 1 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of TJP1 protein] |
CTD |
PMID:28973641 |
|
NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression increases expression multiple interactions |
EXP |
Carnitine results in decreased expression of TNF protein Carnitine deficiency results in increased expression of TNF mRNA [Carboplatin co-treated with Carnitine deficiency] results in increased expression of TNF protein; Acetaminophen promotes the reaction [Carnitine deficiency results in increased expression of TNF mRNA]; Carnitine inhibits the reaction [carbendazim results in increased expression of TNF protein]; Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of TNF mRNA]]; Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of TNF protein]] |
CTD |
PMID:18597074 PMID:18629605 PMID:18852009 PMID:26562095 PMID:33965443 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Vim |
vimentin |
multiple interactions |
EXP |
Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of VIM protein] |
CTD |
PMID:28973641 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
1,2-Dipalmitoylphosphatidylcholine inhibits the reaction [Asbestos, Crocidolite results in increased secretion of IL6 protein] |
CTD |
PMID:19041333 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Prnp |
prion protein |
multiple interactions affects folding |
ISO |
Copper affects the reaction [1,2-Dipalmitoylphosphatidylcholine affects the folding of PRNP protein modified form] |
CTD |
PMID:20936829 |
|
NCBI chr 3:119,186,073...119,201,513
Ensembl chr 3:119,177,485...119,203,937
|
|
|
G |
Fech |
ferrochelatase |
affects abundance |
ISO |
FECH protein affects the abundance of 1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine |
CTD |
PMID:29906468 |
|
NCBI chr18:57,945,123...57,978,327
Ensembl chr18:57,945,122...57,979,348
|
|
|
G |
Fech |
ferrochelatase |
affects abundance |
ISO |
FECH protein affects the abundance of 1-palmitoyl-2-linoleoylphosphatidylcholine |
CTD |
PMID:29906468 |
|
NCBI chr18:57,945,123...57,978,327
Ensembl chr18:57,945,122...57,979,348
|
|
|
G |
Nr5a2 |
nuclear receptor subfamily 5, group A, member 2 |
multiple interactions |
ISO |
[NR5A2 gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of 1-oleoyl lysophosphatidylcholine |
CTD |
PMID:29515023 |
|
NCBI chr13:48,313,634...48,433,494
Ensembl chr13:48,316,301...48,433,326
|
|
G |
Smad3 |
SMAD family member 3 |
decreases abundance |
ISO |
SMAD3 protein results in decreased abundance of 1-oleoyl lysophosphatidylcholine |
CTD |
PMID:23034213 |
|
NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960
|
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of AGTR1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of ALOX5 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Ccr2 |
C-C motif chemokine receptor 2 |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of CCR2 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100
|
|
G |
Cd68 |
Cd68 molecule |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of CD68 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697
|
|
G |
Crp |
C-reactive protein |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of CRP mRNA |
CTD |
PMID:16386258 |
|
NCBI chr13:85,131,635...85,175,179
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
increases phosphorylation multiple interactions |
EXP |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of GJA1 protein AG 1879 inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of GJA1 protein]; resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of GJA1 protein] |
CTD |
PMID:24079413 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of IL1A mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of IL1B mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Kcnab2 |
potassium voltage-gated channel subfamily A regulatory beta subunit 2 |
multiple interactions |
EXP |
[KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine |
CTD |
PMID:21296056 |
|
NCBI chr 5:162,899,511...162,988,057
Ensembl chr 5:162,901,896...162,988,243
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
EXP |
resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:24079413 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
EXP |
resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:24079413 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Olr1 |
oxidized low density lipoprotein receptor 1 |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of OLR1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523
|
|
G |
Ptafr |
platelet-activating factor receptor |
affects binding multiple interactions |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine binds to PTAFR protein 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine inhibits the reaction [Platelet Activating Factor binds to PTAFR protein] |
CTD |
PMID:16386258 |
|
NCBI chr 5:144,765,770...144,795,057
Ensembl chr 5:144,765,976...144,795,251
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of PTGS1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of PTGS2 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Sele |
selectin E |
increases expression increases secretion |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of SELE mRNA 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased secretion of SELE protein |
CTD |
PMID:16386258 |
|
NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions increases phosphorylation |
EXP |
resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of SRC protein] |
CTD |
PMID:24079413 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Timp4 |
TIMP metallopeptidase inhibitor 4 |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of TIMP4 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 4:148,306,021...148,312,558
Ensembl chr 4:148,304,490...148,312,558
|
|
G |
Tnf |
tumor necrosis factor |
increases expression increases secretion |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of TNF mRNA 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased secretion of TNF protein |
CTD |
PMID:16386258 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Lipg |
lipase G, endothelial type |
increases hydrolysis |
ISO |
LIPG protein results in increased hydrolysis of 1-O-hexadecyl-2-arachidonyl-sn-glycero-3-phosphocholine |
CTD |
PMID:15953354 |
|
NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260
|
|
|
G |
Lipc |
lipase C, hepatic type |
multiple interactions |
ISO |
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of stearoyl alpha-lysolecithin |
CTD |
PMID:24777581 |
|
NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464
|
|
G |
Lipg |
lipase G, endothelial type |
multiple interactions |
ISO |
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of stearoyl alpha-lysolecithin |
CTD |
PMID:24777581 |
|
NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260
|
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of AGTR1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Alox12 |
arachidonate 12-lipoxygenase, 12S type |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of ALOX12 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr10:54,958,263...54,970,542
Ensembl chr10:54,958,271...54,970,542
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions increases expression |
ISO |
[sodium arsenite co-treated with Platelet Activating Factor co-treated with Arachidonic Acid] results in increased phosphorylation of and results in increased activity of ALOX5 protein; [zileuton results in decreased activity of ALOX5 protein] inhibits the reaction [Calcimycin results in increased abundance of Platelet Activating Factor] Platelet Activating Factor results in increased expression of ALOX5 mRNA |
CTD |
PMID:8387780 PMID:10779545 PMID:16386258 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions increases secretion |
ISO |
Foropafant inhibits the reaction [Platelet Activating Factor results in increased secretion of CCL2 protein] |
CTD |
PMID:15149885 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccr2 |
C-C motif chemokine receptor 2 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of CCR2 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100
|
|
G |
Crp |
C-reactive protein |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of CRP mRNA |
CTD |
PMID:16386258 |
|
NCBI chr13:85,131,635...85,175,179
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Cx3cr1 |
C-X3-C motif chemokine receptor 1 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of CX3CR1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 8:119,785,726...119,799,431
Ensembl chr 8:119,782,595...119,800,014
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions increases abundance |
EXP |
Carbon Tetrachloride promotes the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]; EDNRB protein affects the reaction [Carbon Tetrachloride promotes the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]]; EDNRB protein affects the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor] |
CTD |
PMID:18205269 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Ednrb |
endothelin receptor type B |
multiple interactions |
EXP |
EDNRB protein affects the reaction [Carbon Tetrachloride promotes the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]]; EDNRB protein affects the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor] |
CTD |
PMID:18205269 |
|
NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115
|
|
G |
Egr1 |
early growth response 1 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of EGR1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr18:26,463,333...26,465,531
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Gusb |
glucuronidase, beta |
multiple interactions |
EXP |
[Platelet Activating Factor co-treated with Cytochalasin B] results in increased secretion of GUSB protein; IMMLG5521 inhibits the reaction [[Platelet Activating Factor co-treated with Cytochalasin B] results in increased secretion of GUSB protein] |
CTD |
PMID:23850278 |
|
NCBI chr12:26,701,191...26,714,718
Ensembl chr12:26,697,951...26,726,905
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of IL1A mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
increases expression multiple interactions increases secretion |
ISO |
Platelet Activating Factor results in increased expression of IL1B mRNA [Platelet Activating Factor co-treated with MIR149 mRNA] affects the secretion of IL1B protein; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL1B protein] |
CTD |
PMID:16386258 PMID:32830409 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases secretion |
ISO |
[Platelet Activating Factor co-treated with MIR149 mRNA] affects the secretion of IL6 protein; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL6 protein] |
CTD |
PMID:32830409 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Itgam |
integrin subunit alpha M |
multiple interactions increases expression |
ISO |
Foropafant inhibits the reaction [Platelet Activating Factor results in increased expression of ITGAM protein]; Isoproterenol promotes the reaction [Theophylline inhibits the reaction [Platelet Activating Factor results in increased expression of ITGAM protein]]; Theophylline inhibits the reaction [Platelet Activating Factor results in increased expression of ITGAM protein] |
CTD |
PMID:9762784 PMID:11116075 |
|
NCBI chr 1:182,659,047...182,709,495
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Ltb4r |
leukotriene B4 receptor |
affects response to substance |
ISO |
LTB4R1 protein affects the susceptibility to Platelet Activating Factor |
CTD |
PMID:10934231 |
|
NCBI chr15:29,263,126...29,265,716
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of MMP13 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
increases expression multiple interactions |
ISO |
Platelet Activating Factor results in increased expression of MYD88 protein PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased expression of MYD88 protein] |
CTD |
PMID:32830409 |
|
NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Nceh1 |
neutral cholesterol ester hydrolase 1 |
multiple interactions |
ISO |
NCEH1 protein inhibits the reaction [[Chlorpyrifos metabolite co-treated with Cytidine Diphosphate Choline] results in increased abundance of Platelet Activating Factor] |
CTD |
PMID:18164358 |
|
NCBI chr 2:110,074,985...110,135,592
Ensembl chr 2:110,074,957...110,135,588
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions increases degradation |
ISO |
Acetylcysteine inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; BN 50739 inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; Genistein inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; herbimycin inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; pyrrolidine dithiocarbamic acid inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; Tosylphenylalanyl Chloromethyl Ketone inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; Vitamin E inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein] |
CTD |
PMID:10921504 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Olr1 |
oxidized low density lipoprotein receptor 1 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of OLR1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523
|
|
G |
Pla2g7 |
phospholipase A2 group VII |
multiple interactions increases expression |
ISO |
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Platelet Activating Factor] results in increased expression of PLA2G7 mRNA; bepafant inhibits the reaction [Platelet Activating Factor results in increased expression of PLA2G7 mRNA] |
CTD |
PMID:21432021 |
|
NCBI chr 9:17,362,214...17,404,476
Ensembl chr 9:17,362,225...17,404,476
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
decreases expression |
ISO |
Platelet Activating Factor results in decreased expression of PPARA mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ptafr |
platelet-activating factor receptor |
multiple interactions increases expression increases phosphorylation affects binding |
ISO EXP |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; BN 50730 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; BN 50739 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; CMI 392 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; MK 287 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; zileuton inhibits the reaction [Platelet Activating Factor binds to PTAFR protein] Platelet Activating Factor results in increased expression of PTAFR mRNA Platelet Activating Factor results in increased phosphorylation of PTAFR protein bepafant inhibits the reaction [Platelet Activating Factor results in increased expression of PTAFR mRNA]; Carbon Tetrachloride promotes the reaction [Platelet Activating Factor binds to PTAFR protein]; RGS4 protein inhibits the reaction [Platelet Activating Factor results in increased phosphorylation of PTAFR protein]; TNF protein affects the reaction [Platelet Activating Factor results in increased expression of PTAFR mRNA] |
CTD |
PMID:9065783 PMID:10447766 PMID:11297424 PMID:11529688 PMID:16386258 PMID:18205269 More...
|
|
NCBI chr 5:144,765,770...144,795,057
Ensembl chr 5:144,765,976...144,795,251
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of PTGS1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of PTGS2 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pvt1 |
Pvt1 oncogene |
multiple interactions increases expression |
ISO |
[Platelet Activating Factor co-treated with PVT1 mRNA] affects the expression of MIR149 mRNA; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased expression of MYD88 protein]; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL1B protein]; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL6 protein]; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of TNF protein] Platelet Activating Factor results in increased expression of PVT1 mRNA |
CTD |
PMID:32830409 |
|
NCBI chr 7:93,656,249...93,879,938
|
|
G |
Rgs4 |
regulator of G-protein signaling 4 |
multiple interactions |
EXP |
RGS4 protein inhibits the reaction [Platelet Activating Factor results in increased phosphorylation of PTAFR protein] |
CTD |
PMID:11297424 |
|
NCBI chr13:81,936,775...81,943,103
Ensembl chr13:81,936,775...81,943,068
|
|
G |
Sele |
selectin E |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of SELE mRNA |
CTD |
PMID:16386258 |
|
NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Sell |
selectin L |
increases secretion multiple interactions |
ISO |
Platelet Activating Factor results in increased secretion of SELL protein Isoproterenol promotes the reaction [Theophylline inhibits the reaction [Platelet Activating Factor results in increased secretion of SELL protein]]; Theophylline inhibits the reaction [Platelet Activating Factor results in increased secretion of SELL protein] |
CTD |
PMID:9762784 |
|
NCBI chr13:76,416,969...76,436,444
Ensembl chr13:76,416,915...76,436,456
|
|
G |
Selp |
selectin P |
multiple interactions increases expression |
ISO |
Foropafant inhibits the reaction [Platelet Activating Factor results in increased expression of SELP protein] |
CTD |
PMID:11116075 |
|
NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845
|
|
G |
Timp4 |
TIMP metallopeptidase inhibitor 4 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of TIMP4 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 4:148,306,021...148,312,558
Ensembl chr 4:148,304,490...148,312,558
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression increases secretion |
EXP ISO |
TNF protein affects the reaction [Platelet Activating Factor results in increased expression of PTAFR mRNA] [Platelet Activating Factor co-treated with MIR149 mRNA] affects the secretion of TNF protein; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of TNF protein] Platelet Activating Factor results in increased expression of TNF mRNA Acetylcysteine inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA]; BN 50739 inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA]; Vitamin E inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA] |
CTD |
PMID:9065783 PMID:10921504 PMID:16386258 PMID:32830409 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Tnf |
tumor necrosis factor |
increases expression |
EXP |
platelet-activating factor increases expression of Tnf protein in portal stenosis rat plasma |
RGD |
PMID:10452877 |
RGD:38508900 |
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
multiple interactions increases abundance |
ISO |
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of 3-dehydrocarnitine] |
CTD |
PMID:27469509 |
|
NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
|
|
|
G |
Bbox1 |
gamma-butyrobetaine hydroxylase 1 |
multiple interactions |
ISO |
[BBOX1 protein co-treated with Ketoglutaric Acids] results in increased metabolism of gamma-butyrobetaine |
CTD |
PMID:21439360 |
|
NCBI chr 3:96,822,654...96,871,786
Ensembl chr 3:96,822,655...96,871,458
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
multiple interactions increases abundance |
ISO |
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of gamma-butyrobetaine] |
CTD |
PMID:27469509 |
|
NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
|
|
|
G |
Slc22a5 |
solute carrier family 22 member 5 |
increases uptake multiple interactions affects binding increases transport |
ISO EXP |
SLC22A5 protein results in increased uptake of pivaloylcarnitine Carnitine inhibits the reaction [SLC22A5 protein results in increased transport of pivaloylcarnitine]; pivaloylcarnitine inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine] pivaloylcarnitine binds to SLC22A5 protein |
CTD |
PMID:18762717 PMID:19539806 |
|
NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309
|
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions |
ISO |
Ergothioneine inhibits the reaction [Cisplatin results in decreased activity of ACHE protein] |
CTD |
PMID:20932872 |
|
NCBI chr12:19,407,359...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:33580994 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of CASP3 protein] |
CTD |
PMID:33580994 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased activity of CAT protein] |
CTD |
PMID:33580994 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of FOS protein] |
CTD |
PMID:33580994 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of GPT protein] |
CTD |
PMID:33580994 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL6 protein] |
CTD |
PMID:33580994 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Pik3ca |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha |
multiple interactions |
EXP |
Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of PIK3CA protein] |
CTD |
PMID:33580994 |
|
NCBI chr 2:115,175,275...115,249,034
Ensembl chr 2:115,174,984...115,249,032
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which affects the localization of RELA protein] |
CTD |
PMID:33580994 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TNF protein] |
CTD |
PMID:33580994 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of ABCC4 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Abi3bp |
ABI family member 3 binding protein |
increases expression |
EXP |
Betaine results in increased expression of ABI3BP mRNA |
CTD |
PMID:26391144 |
|
NCBI chr11:43,912,187...44,128,888
Ensembl chr11:43,913,043...44,128,929
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions |
EXP |
[Choline co-treated with Betaine co-treated with Vitamin B 12 co-treated with Folic Acid co-treated with Dietary Fats co-treated with Dietary Sucrose] results in increased expression of ACACA mRNA |
CTD |
PMID:22648174 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acacb |
acetyl-CoA carboxylase beta |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of ACACB mRNA |
CTD |
PMID:33549593 |
|
NCBI chr12:42,365,800...42,477,651
Ensembl chr12:42,366,548...42,457,655
|
|
G |
Adgrg2 |
adhesion G protein-coupled receptor G2 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of ADGRG2 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr X:34,297,402...34,422,590
Ensembl chr X:34,297,402...34,422,609
|
|
G |
Adss |
adenylosuccinate synthase |
decreases expression |
EXP |
Betaine results in decreased expression of ADSS mRNA |
CTD |
PMID:26391144 |
|
NCBI chr13:89,769,240...89,799,577
Ensembl chr13:89,769,244...89,799,604
|
|
G |
Ahcy |
adenosylhomocysteinase |
decreases expression |
ISO EXP |
Betaine results in decreased expression of AHCY mRNA |
CTD |
PMID:22945834 PMID:26391144 |
|
NCBI chr 3:143,569,134...143,584,359
Ensembl chr 3:143,569,094...143,584,393
|
|
G |
Akip1 |
A-kinase interacting protein 1 |
increases expression |
EXP |
Betaine results in increased expression of AKIP1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 1:163,734,730...163,743,648
Ensembl chr 1:163,734,798...163,743,648
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B1 |
decreases expression |
EXP |
Betaine results in decreased expression of AKR1B1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157
|
|
G |
Akr1b7 |
aldo-keto reductase family 1, member B7 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of AKR1B7 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 4:63,053,560...63,100,934
Ensembl chr 4:63,076,800...63,089,502
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
multiple interactions |
ISO |
[Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate co-treated with Ethanol] results in increased expression of ALDH2 protein |
CTD |
PMID:20118189 |
|
NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521
|
|
G |
Apex1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
decreases expression |
EXP |
Betaine results in decreased expression of APEX1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
Betaine inhibits the reaction [Azacitidine results in decreased methylation of APP promoter]; Betaine inhibits the reaction [Azacitidine results in increased expression of and results in increased cleavage of APP protein]; Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased methylation of APP promoter]; Betaine inhibits the reaction [S-Adenosylhomocysteine results in increased expression of and results in increased cleavage of APP protein] |
CTD |
PMID:19635394 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Atp7b |
ATPase copper transporting beta |
multiple interactions |
ISO |
ATP7B protein mutant form promotes the reaction [Betaine results in increased abundance of S-Adenosylmethionine]; Betaine inhibits the reaction [ATP7B protein mutant form results in increased abundance of Copper]; Betaine inhibits the reaction [ATP7B protein mutant form results in increased expression of TNF mRNA] |
CTD |
PMID:22945834 |
|
NCBI chr16:69,952,286...70,024,404
Ensembl chr16:69,951,778...70,023,636
|
|
G |
Axin1 |
axin 1 |
multiple interactions |
ISO |
[Folic Acid co-treated with Vitamin B 12 co-treated with Betaine co-treated with Choline] results in increased methylation of AXIN1 gene |
CTD |
PMID:16868943 |
|
NCBI chr10:15,163,684...15,215,615
Ensembl chr10:15,163,684...15,215,615
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
decreases expression |
EXP |
Betaine results in decreased expression of BAX protein |
CTD |
PMID:25080425 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
affects binding increases expression |
ISO EXP |
Betaine analog binds to BCL2 protein Betaine results in increased expression of BCL2 protein |
CTD |
PMID:25080425 PMID:25765238 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bhlhe40 |
basic helix-loop-helix family, member e40 |
increases expression |
EXP |
Betaine results in increased expression of BHLHE40 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 4:141,618,453...141,624,154
Ensembl chr 4:141,618,476...141,624,774
|
|
G |
Bhmt |
betaine-homocysteine S-methyltransferase |
increases metabolic processing |
ISO |
BHMT protein results in increased metabolism of Betaine |
CTD |
PMID:18230605 |
|
NCBI chr 2:24,859,871...24,879,449
Ensembl chr 2:24,859,873...24,879,742
|
|
G |
Brf1 |
BRF1, RNA polymerase III transcription initiation factor subunit |
multiple interactions |
ISO |
Betaine inhibits the reaction [Ethanol results in increased expression of BRF1 mRNA]; Betaine inhibits the reaction [Ethanol results in increased expression of BRF1 protein] |
CTD |
PMID:32418914 |
|
NCBI chr 6:132,034,380...132,081,296
Ensembl chr 6:132,037,272...132,081,278
|
|
G |
Cab39l |
calcium binding protein 39-like |
decreases expression |
EXP |
Betaine results in decreased expression of CAB39L mRNA |
CTD |
PMID:26391144 |
|
NCBI chr15:33,606,588...33,710,518
Ensembl chr15:33,606,694...33,743,545
|
|
G |
Casp1 |
caspase 1 |
increases expression |
EXP |
Betaine results in increased expression of CASP1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
Betaine inhibits the reaction [Cadmium Chloride results in increased activity of CASP3 protein] |
CTD |
PMID:24632105 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions |
ISO EXP |
[Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate co-treated with Ethanol] results in increased activity of CAT protein Betaine inhibits the reaction [Cadmium Chloride results in decreased activity of CAT protein]; Betaine inhibits the reaction [Carbon Tetrachloride results in increased activity of CAT protein] |
CTD |
PMID:12893363 PMID:20118189 PMID:24632105 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccdc113 |
coiled-coil domain containing 113 |
increases expression |
EXP |
Betaine results in increased expression of CCDC113 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr19:9,497,000...9,516,917
Ensembl chr19:9,496,886...9,516,923
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
EXP |
[Choline co-treated with Betaine co-treated with Vitamin B 12 co-treated with Folic Acid co-treated with Dietary Fats co-treated with Dietary Sucrose] results in decreased expression of CCL2 mRNA |
CTD |
PMID:22648174 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
increases expression |
EXP |
Betaine results in increased expression of CCL5 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr10:68,322,826...68,327,365
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccl9 |
C-C motif chemokine ligand 9 |
increases expression |
EXP |
Betaine results in increased expression of CCL6 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr10:68,366,486...68,371,408
Ensembl chr10:68,366,487...68,371,369
|
|
G |
Ccnb2 |
cyclin B2 |
decreases expression |
EXP |
Betaine results in decreased expression of CCNB2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 8:71,087,594...71,100,794
Ensembl chr 8:71,087,595...71,100,874
|
|
G |
Cd44 |
CD44 molecule (Indian blood group) |
decreases expression |
EXP |
Betaine results in decreased expression of CD44 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Cdc42ep2 |
CDC42 effector protein 2 |
decreases expression |
EXP |
Betaine results in decreased expression of CDC42EP2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 1:203,202,000...203,210,891
Ensembl chr 1:203,201,873...203,210,897
|
|
G |
Cdh13 |
cadherin 13 |
decreases expression |
EXP |
Betaine results in decreased expression of CDH13 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr19:46,349,562...47,387,462
Ensembl chr19:46,349,430...47,387,459
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CDK1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
multiple interactions |
EXP |
Betaine promotes the reaction [Diethylnitrosamine results in decreased expression of CDKN2A mRNA] |
CTD |
PMID:19642983 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Ces2c |
carboxylesterase 2C |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CES2C mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:260,391,190...260,398,757
Ensembl chr 1:260,388,902...260,398,790
|
|
G |
Ces3a |
carboxylesterase 3a |
increases expression |
EXP |
Betaine results in increased expression of CES3 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr19:32,992,386...33,000,562
|
|
G |
Ckb |
creatine kinase B |
increases expression |
EXP |
Betaine results in increased expression of CKB mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 6:130,729,420...130,732,301
Ensembl chr 6:130,729,423...130,732,315
|
|
G |
Cks1b |
CDC28 protein kinase regulatory subunit 1B |
decreases expression |
EXP |
Betaine results in decreased expression of CKS1B mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 2:174,833,025...174,837,614
Ensembl chr 2:174,833,050...174,837,636
|
|
G |
Clcf1 |
cardiotrophin-like cytokine factor 1 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CLCF1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:201,507,763...201,517,607
Ensembl chr 1:201,507,859...201,517,605
|
|
G |
Cotl1 |
coactosin-like F-actin binding protein 1 |
decreases expression |
EXP |
Betaine results in decreased expression of COTL1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr19:47,871,689...47,906,010
Ensembl chr19:47,871,694...47,911,689
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions decreases expression |
ISO |
Betaine inhibits the reaction [CPT1A protein mutant form results in decreased expression of DNMT1 mRNA] Betaine results in decreased expression of CPT1A mRNA |
CTD |
PMID:22945834 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Cxcl16 |
C-X-C motif chemokine ligand 16 |
decreases expression |
EXP |
Betaine results in decreased expression of CXCL16 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr10:55,166,721...55,171,316
Ensembl chr10:55,166,723...55,171,592
|
|
G |
Cyp26a1 |
cytochrome P450, family 26, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CYP26A1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:235,471,368...235,475,204
Ensembl chr 1:235,471,298...235,475,204
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CYP2B10 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2c24 |
cytochrome P450, family 2, subfamily c, polypeptide 24 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CYP2C55 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:236,873,967...236,936,238
Ensembl chr 1:236,873,967...236,936,238
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
ISO |
[Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate] inhibits the reaction [Ethanol results in increased expression of CYP2E1 protein] Betaine promotes the reaction [Ethanol results in increased expression of CYP2E1] |
CTD |
PMID:20118189 PMID:21352821 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cysltr1 |
cysteinyl leukotriene receptor 1 |
increases expression |
EXP |
Betaine results in increased expression of CYSLTR1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr X:71,661,415...71,690,158
Ensembl chr X:71,663,821...71,690,121
|
|
G |
Dapk1 |
death associated protein kinase 1 |
decreases expression |
EXP |
Betaine results in decreased expression of DAPK1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr17:3,930,223...4,090,991
Ensembl chr17:3,930,213...4,090,991
|
|
G |
Depp1 |
DEPP autophagy regulator 1 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of DEPP1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 4:149,910,794...149,913,013
Ensembl chr 4:149,910,779...149,914,542
|
|
G |
Dlx2 |
distal-less homeobox 2 |
increases expression |
EXP |
Betaine results in increased expression of DLX2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 3:56,371,347...56,373,230
Ensembl chr 3:56,370,483...56,373,597
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
multiple interactions increases expression |
ISO |
Betaine inhibits the reaction [CPT1A protein mutant form results in decreased expression of DNMT1 mRNA] Betaine results in increased expression of DNMT1 mRNA |
CTD |
PMID:22945834 |
|
NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
|
|
G |
Dnmt3b |
DNA methyltransferase 3 beta |
decreases expression |
ISO |
Betaine results in decreased expression of DNMT3B mRNA |
CTD |
PMID:22945834 |
|
NCBI chr 3:142,130,592...142,169,124
Ensembl chr 3:142,130,592...142,169,124
|
|
G |
E2f8 |
E2F transcription factor 8 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of E2F8 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:98,565,717...98,584,265
Ensembl chr 1:98,565,717...98,584,098
|
|
G |
Ect2 |
epithelial cell transforming 2 |
decreases expression |
EXP |
Betaine results in decreased expression of ECT2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 2:109,975,813...110,037,911
Ensembl chr 2:109,975,813...110,037,911
|
|
G |
Eef2k |
eukaryotic elongation factor-2 kinase |
increases expression |
EXP |
Betaine results in increased expression of EEF2K mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 1:175,393,119...175,454,452
Ensembl chr 1:175,393,154...175,455,164
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of EGFR mRNA |
CTD |
PMID:33549593 |
|
NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egr1 |
early growth response 1 |
increases expression multiple interactions |
EXP ISO |
Betaine results in increased expression of EGR1 mRNA [Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of EGR1 mRNA |
CTD |
PMID:26391144 PMID:33549593 |
|
NCBI chr18:26,463,333...26,465,531
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Elf3 |
E74 like ETS transcription factor 3 |
decreases expression |
EXP |
Betaine results in decreased expression of ELF3 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr13:46,690,460...46,695,394
Ensembl chr13:46,690,466...46,695,481
|
|
G |
Emc9 |
ER membrane protein complex subunit 9 |
increases expression |
EXP |
Betaine results in increased expression of EMC9 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr15:29,071,881...29,076,098
Ensembl chr15:29,071,883...29,076,098
|
|
G |
Ephb6 |
Eph receptor B6 |
increases expression |
EXP |
Betaine results in increased expression of EPHB6 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 4:70,491,973...70,507,230
Ensembl chr 4:70,491,973...70,507,230
|
|
G |
Esco2 |
establishment of sister chromatid cohesion N-acetyltransferase 2 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of ESCO2 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr15:40,034,566...40,052,295
Ensembl chr15:40,034,568...40,055,306
|
|
G |
F8 |
coagulation factor VIII |
multiple interactions increases secretion |
ISO |
Betaine affects the localization of and results in increased secretion of F8 protein; Betaine affects the localization of and results in increased secretion of F8 protein mutant form Betaine results in increased secretion of F8 protein; Betaine results in increased secretion of F8 protein mutant form |
CTD |
PMID:22973456 |
|
NCBI chr18:140,848...172,330
Ensembl chr18:140,955...171,857
|
|
G |
F9 |
coagulation factor IX |
increases secretion |
ISO |
Betaine results in increased secretion of F9 protein |
CTD |
PMID:22973456 |
|
NCBI chr X:138,352,334...138,396,835
Ensembl chr X:138,352,298...138,396,835
|
|
G |
Fabp5 |
fatty acid binding protein 5 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of FABP5 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 2:91,765,056...91,768,716
Ensembl chr 2:91,765,056...91,853,773
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
EXP |
[Choline co-treated with Betaine co-treated with Vitamin B 12 co-treated with Folic Acid] affects the reaction [[Dietary Fats co-treated with Dietary Sucrose] affects the methylation of FASN promoter] |
CTD |
PMID:22648174 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Flrt3 |
fibronectin leucine rich transmembrane protein 3 |
increases expression |
EXP |
Betaine results in increased expression of FLRT3 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 3:127,994,491...128,008,137
Ensembl chr 3:127,994,226...128,007,841
|
|
G |
Fxyd2 |
FXYD domain-containing ion transport regulator 2 |
decreases expression |
EXP |
Betaine results in decreased expression of FXYD2 mRNA; Betaine results in decreased expression of FXYD2 mRNA alternative form |
CTD |
PMID:26391144 |
|
NCBI chr 8:45,712,887...45,720,032
Ensembl chr 8:45,712,903...45,720,203
|
|
G |
Gadd45b |
growth arrest and DNA-damage-inducible, beta |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of GADD45B mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046
|
|
G |
Gadd45g |
growth arrest and DNA-damage-inducible, gamma |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of GADD45G mRNA |
CTD |
PMID:33549593 |
|
NCBI chr17:13,376,842...13,378,587
Ensembl chr17:13,376,839...13,378,610
|
|
G |
Gal |
galanin and GMAP prepropeptide |
multiple interactions |
EXP |
Betaine inhibits the reaction [Isoproterenol results in decreased activity of GAL protein]; Betaine inhibits the reaction [Isoproterenol results in increased activity of GAL protein] |
CTD |
PMID:19294532 |
|
NCBI chr 1:200,650,439...200,655,302
Ensembl chr 1:200,650,439...200,654,959
|
|
G |
Gck |
glucokinase |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in increased expression of GCK mRNA |
CTD |
PMID:33549593 |
|
NCBI chr14:80,785,060...80,829,842
Ensembl chr14:80,785,060...80,826,995
|
|
G |
Gna14 |
G protein subunit alpha 14 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of GNA14 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:213,714,993...213,900,083
Ensembl chr 1:213,716,020...213,897,423
|
|
G |
Gpcpd1 |
glycerophosphocholine phosphodiesterase 1 |
increases expression multiple interactions |
EXP ISO |
Betaine results in increased expression of GPCPD1 mRNA [Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of GPCPD1 mRNA |
CTD |
PMID:26391144 PMID:33549593 |
|
NCBI chr 3:119,787,681...119,832,550
Ensembl chr 3:119,787,682...119,832,517
|
|
G |
Gsta5 |
glutathione S-transferase alpha 5 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of GSTA5 mRNA; [Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in increased expression of GSTA5 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 8:79,105,561...79,117,472
Ensembl chr 8:79,105,661...79,117,472
|
|
G |
Gstm5 |
glutathione S-transferase, mu 5 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of GSTM3 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 2:195,531,627...195,534,562
Ensembl chr 2:195,531,495...195,534,553
|
|
G |
Gusb |
glucuronidase, beta |
multiple interactions |
EXP |
Betaine inhibits the reaction [Isoproterenol results in decreased activity of GUSB protein]; Betaine inhibits the reaction [Isoproterenol results in increased activity of GUSB protein] |
CTD |
PMID:19294532 |
|
NCBI chr12:26,701,191...26,714,718
Ensembl chr12:26,697,951...26,726,905
|
|
G |
H2az1 |
H2A.Z variant histone 1 |
decreases expression |
EXP |
Betaine results in decreased expression of H2AZ1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 2:226,355,769...226,357,878
Ensembl chr 2:226,355,708...226,358,485
|
|
G |
Hip1 |
huntingtin interacting protein 1 |
decreases expression |
EXP |
Betaine results in decreased expression of HIP1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr12:21,133,319...21,267,796
Ensembl chr12:21,133,406...21,267,725
|
|
G |
Hmgb2 |
high mobility group box 2 |
decreases expression |
EXP |
Betaine results in decreased expression of HMGB2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr16:32,710,651...32,713,230
Ensembl chr16:32,710,658...32,713,140
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
decreases expression |
ISO |
Betaine results in decreased expression of HSPA5 mRNA |
CTD |
PMID:22945834 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Id2 |
inhibitor of DNA binding 2 |
increases expression |
EXP |
Betaine results in increased expression of ID2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 6:41,740,556...41,742,393
Ensembl chr 6:41,728,946...41,744,400
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
increases abundance multiple interactions |
ISO |
IDH2 protein mutant form results in increased abundance of Betaine Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Betaine] |
CTD |
PMID:27469509 |
|
NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
|
|
G |
Irs2 |
insulin receptor substrate 2 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of IRS2 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr16:78,488,249...78,512,482
Ensembl chr16:78,485,045...78,512,482
|
|
G |
Irx4 |
iroquois homeobox 4 |
decreases expression |
EXP |
Betaine results in decreased expression of IRX4 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 1:30,030,561...30,039,549
Ensembl chr 1:30,030,561...30,039,549
|
|
G |
Itga8 |
integrin subunit alpha 8 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of ITGA8 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr17:75,304,004...75,501,510
Ensembl chr17:75,304,008...75,501,510
|
|
G |
Itgb4 |
integrin subunit beta 4 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of ITGB4 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr10:101,206,657...101,243,012
Ensembl chr10:101,206,665...101,243,012
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases expression |
EXP |
Betaine results in increased expression of JUN mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Khdrbs3 |
KH RNA binding domain containing, signal transduction associated 3 |
decreases expression |
EXP |
Betaine results in decreased expression of KHDRBS3 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 7:100,837,707...100,995,644
Ensembl chr 7:100,837,934...100,988,460
|
|
G |
Kif1b |
kinesin family member 1B |
increases expression |
EXP |
Betaine results in increased expression of KIF1B mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 5:159,607,697...159,742,778
Ensembl chr 5:159,561,271...159,742,778
|
|
G |
Kif22 |
kinesin family member 22 |
decreases expression |
EXP |
Betaine results in decreased expression of KIF22 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 1:181,635,347...181,650,351
Ensembl chr 1:181,635,183...181,650,401
|
|
G |
Klf10 |
KLF transcription factor 10 |
increases expression |
EXP |
Betaine results in increased expression of KLF10 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 7:69,467,658...69,473,726
Ensembl chr 7:69,465,619...69,473,994
|
|
G |
Krt2 |
keratin 2 |
increases expression |
EXP |
Betaine results in increased expression of KRT2 mRNA; Betaine results in increased expression of KRT2 protein |
CTD |
PMID:26391144 |
|
NCBI chr 7:132,941,275...132,947,963
Ensembl chr 7:132,940,862...132,947,963
|
|
G |
Krt4 |
keratin 4 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of KRT4 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 7:133,046,067...133,052,027
Ensembl chr 7:133,046,515...133,052,019
|
|
G |
Lars1 |
leucyl-tRNA synthetase 1 |
decreases expression |
EXP |
Betaine results in decreased expression of LARS mRNA |
CTD |
PMID:26391144 |
|
NCBI chr18:34,201,555...34,256,003
Ensembl chr18:34,201,549...34,255,931
|
|
G |
Lepr |
leptin receptor |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of LEPR mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
|
|
G |
Lin9 |
lin-9 DREAM MuvB core complex component |
decreases expression |
EXP |
Betaine results in decreased expression of LIN9 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr13:92,374,612...92,419,664
Ensembl chr13:92,374,593...92,419,654
|
|
G |
Lratd1 |
LRAT domain containing 1 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of LRATD1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 6:36,916,969...36,922,143
Ensembl chr 6:36,913,469...36,922,319
|
|
G |
Lrrc24 |
leucine rich repeat containing 24 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of LRRC24 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 7:108,437,296...108,444,561
Ensembl chr 7:108,437,296...108,444,438
|
|
G |
Map4k1 |
mitogen activated protein kinase kinase kinase kinase 1 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of MAP4K1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:84,270,951...84,292,496
Ensembl chr 1:84,271,069...84,292,493
|
|
G |
Marchf6 |
membrane associated ring-CH-type finger 6 |
multiple interactions decreases stability |
ISO |
Cholesterol inhibits the reaction [Betaine results in decreased stability of MARCHF6 protein] |
CTD |
PMID:30545937 |
|
NCBI chr 2:82,455,686...82,532,917
Ensembl chr 2:82,455,689...82,532,910
|
|
G |
Mcm3 |
minichromosome maintenance complex component 3 |
decreases expression |
EXP |
Betaine results in decreased expression of MCM3 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 9:23,219,169...23,237,314
Ensembl chr 9:23,219,169...23,237,314
|
|
G |
Mcm4 |
minichromosome maintenance complex component 4 |
decreases expression |
EXP |
Betaine results in decreased expression of MCM4 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr11:85,258,443...85,272,144
Ensembl chr11:85,258,443...85,272,144
|
|
G |
Mcm5 |
minichromosome maintenance complex component 5 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of MCM5 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr19:13,483,030...13,504,389
Ensembl chr19:13,483,066...13,504,389
|
|
G |
Mcm6 |
minichromosome maintenance complex component 6 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of MCM6 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr13:39,826,745...39,851,937
Ensembl chr13:39,826,763...39,851,960
|
|
G |
Mcm7 |
minichromosome maintenance complex component 7 |
decreases expression |
EXP |
Betaine results in decreased expression of MCM7 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr12:17,042,207...17,049,470
Ensembl chr12:17,042,212...17,050,063
|
|
G |
Mical1 |
microtubule associated monooxygenase, calponin and LIM domain containing 1 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of MICAL1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr20:44,974,137...44,986,089
Ensembl chr20:44,974,138...44,986,089
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of MKI67 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mthfd1l |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like |
decreases expression |
EXP |
Betaine results in decreased expression of MTHFD1L mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 1:40,443,926...40,632,911
Ensembl chr 1:40,444,008...40,632,905
|
|
G |
Mthfd2 |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase |
decreases expression |
EXP |
Betaine results in decreased expression of MTHFD2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 4:115,811,135...115,822,663
Ensembl chr 4:115,811,139...115,822,608
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
EXP |
Betaine inhibits the reaction [Diethylnitrosamine results in increased expression of MYC mRNA] |
CTD |
PMID:19642983 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Mycl |
MYCL proto-oncogene, bHLH transcription factor |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of MYCL mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 5:135,274,713...135,281,584
Ensembl chr 5:135,274,748...135,281,582
|
|
G |
Nbl1 |
NBL1, DAN family BMP antagonist |
increases expression |
EXP |
Betaine results in increased expression of NBL1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 5:151,318,752...151,329,948
Ensembl chr 5:151,318,754...151,338,719
|
|
G |
Nckipsd |
NCK interacting protein with SH3 domain |
decreases expression |
EXP |
Betaine results in decreased expression of NCKIPSD mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 8:109,511,484...109,522,625
Ensembl chr 8:109,511,658...109,522,246
|
|
G |
Ndrg4 |
NDRG family member 4 |
decreases expression |
EXP |
Betaine results in decreased expression of NDRG4 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr19:9,351,408...9,387,398
Ensembl chr19:9,351,404...9,386,914
|
|
G |
Nlrp12 |
NLR family, pyrin domain containing 12 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of NLRP12 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:65,932,610...65,969,873
Ensembl chr 1:65,932,595...65,960,934
|
|
G |
Nupr1 |
nuclear protein 1, transcriptional regulator |
decreases expression |
EXP |
Betaine results in decreased expression of NUPR1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 1:181,213,292...181,215,327
|
|
G |
Ogg1 |
8-oxoguanine DNA glycosylase |
multiple interactions |
ISO |
Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased expression of OGG1 protein]; Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased methylation of OGG1 promoter] |
CTD |
PMID:22064374 |
|
NCBI chr 4:146,474,701...146,481,959
Ensembl chr 4:146,474,750...146,484,766
|
|
G |
Pcp4 |
Purkinje cell protein 4 |
increases expression |
EXP |
Betaine results in increased expression of PCP4 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr11:35,759,711...35,861,725
Ensembl chr11:35,800,713...35,861,725
|
|
G |
Pctp |
phosphatidylcholine transfer protein |
decreases expression |
EXP |
Betaine results in decreased expression of PCTP mRNA |
CTD |
PMID:26391144 |
|
NCBI chr10:74,808,887...74,856,260
Ensembl chr10:74,808,887...74,849,867
|
|
G |
Per2 |
period circadian regulator 2 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in increased expression of PER2 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 9:92,007,289...92,049,551
Ensembl chr 9:92,007,296...92,049,459
|
|
G |
Pola2 |
DNA polymerase alpha 2, accessory subunit |
decreases expression |
EXP |
Betaine results in decreased expression of POLA2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 1:203,227,183...203,251,350
Ensembl chr 1:203,203,388...203,251,348
|
|
G |
Pole2 |
DNA polymerase epsilon 2, accessory subunit |
decreases expression |
EXP |
Betaine results in decreased expression of POLE2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 6:87,674,702...87,712,723
Ensembl chr 6:87,674,702...87,699,305
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions decreases expression |
ISO |
[Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate co-treated with Ethanol] results in increased expression of PPARA protein Betaine results in decreased expression of PPARA mRNA |
CTD |
PMID:20118189 PMID:22945834 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppp1r3g |
protein phosphatase 1, regulatory subunit 3G |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of PPP1R3G mRNA |
CTD |
PMID:33549593 |
|
NCBI chr17:28,874,956...28,878,288
Ensembl chr17:28,876,482...28,877,525
|
|
G |
Ppp2ca |
protein phosphatase 2 catalytic subunit alpha |
multiple interactions |
ISO |
Betaine inhibits the reaction [Ethanol results in decreased methylation of PPP2CA protein] |
CTD |
PMID:32492475 |
|
NCBI chr10:36,358,110...36,377,864
Ensembl chr10:36,358,101...36,377,862
|
|
G |
Prss23 |
serine protease 23 |
increases expression |
EXP |
Betaine results in increased expression of PRSS23 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 1:143,402,725...143,422,182
Ensembl chr 1:143,401,396...143,422,091
|
|
G |
Prss8 |
serine protease 8 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of PRSS8 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:182,536,229...182,540,745
Ensembl chr 1:182,536,229...182,540,815
|
|
G |
Psen1 |
presenilin 1 |
multiple interactions |
ISO |
Betaine inhibits the reaction [Azacitidine results in decreased methylation of PSEN1 promoter]; Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased methylation of PSEN1 promoter] |
CTD |
PMID:19635394 |
|
NCBI chr 6:103,323,014...103,375,088
Ensembl chr 6:103,323,120...103,371,650
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
decreases expression |
EXP |
Betaine results in decreased expression of PTGS1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ranbp3l |
RAN binding protein 3-like |
decreases expression |
EXP |
Betaine results in decreased expression of RANBP3L mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 2:58,057,887...58,113,158
Ensembl chr 2:58,058,263...58,113,172
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
Betaine inhibits the reaction [Fructose results in decreased activity of RELA protein] |
CTD |
PMID:25559852 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rfx4 |
regulatory factor X4 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of RFX4 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 7:18,853,065...19,015,378
Ensembl chr 7:18,853,322...19,014,967
|
|
G |
Rgs16 |
regulator of G-protein signaling 16 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of RGS16 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr13:65,887,788...65,891,232
Ensembl chr13:65,887,530...65,892,857
|
|
G |
Rgs2 |
regulator of G-protein signaling 2 |
increases expression |
EXP |
Betaine results in increased expression of RGS2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr13:55,799,749...55,802,354
Ensembl chr13:55,798,829...55,802,385
|
|
G |
Rrm2 |
ribonucleotide reductase regulatory subunit M2 |
decreases expression multiple interactions |
EXP ISO |
Betaine results in decreased expression of RRM2 mRNA [Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of RRM2 mRNA |
CTD |
PMID:26391144 PMID:33549593 |
|
NCBI chr 6:41,339,858...41,346,774
Ensembl chr 6:41,340,557...41,346,773
|
|
G |
S100a8 |
S100 calcium binding protein A8 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of S100A8 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643
|
|
G |
Scd |
stearoyl-CoA desaturase |
decreases expression |
EXP |
Betaine results in decreased expression of SCD1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Sectm1b |
secreted and transmembrane 1B |
increases expression |
EXP |
Betaine results in increased expression of SECTM1A mRNA |
CTD |
PMID:26391144 |
|
NCBI chr10:106,325,202...106,333,769
Ensembl chr10:106,325,203...106,333,769
|
|
G |
Serinc2 |
serine incorporator 2 |
decreases expression |
EXP |
Betaine results in decreased expression of SERINC2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 5:142,592,308...142,614,628
Ensembl chr 5:142,592,309...142,618,364
|
|
G |
Serpina3n |
serine (or cysteine) peptidase inhibitor, clade A, member 3N |
decreases expression |
EXP |
Betaine results in decreased expression of SERPINA3N mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 6:123,323,632...123,331,166
Ensembl chr 6:123,323,629...123,332,433
|
|
G |
Slc16a6 |
solute carrier family 16, member 6 |
increases expression |
EXP |
Betaine results in increased expression of SLC16A6 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr10:94,424,377...94,447,984
Ensembl chr10:94,426,244...94,448,779
|
|
G |
Slc22a5 |
solute carrier family 22 member 5 |
multiple interactions |
ISO |
Betaine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine] |
CTD |
PMID:16928358 |
|
NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309
|
|
G |
Slc25a30 |
solute carrier family 25, member 30 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of SLC25A30 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr15:51,076,998...51,099,613
Ensembl chr15:51,077,002...51,099,613
|
|
G |
Slc36a1 |
solute carrier family 36 member 1 |
increases uptake |
ISO |
SLC36A1 protein results in increased uptake of Betaine |
CTD |
PMID:18845132 |
|
NCBI chr10:39,319,062...39,357,374
Ensembl chr10:39,324,337...39,354,217
|
|
G |
Slc6a12 |
solute carrier family 6 member 12 |
multiple interactions |
ISO |
Betaine inhibits the reaction [Lipopolysaccharides results in increased expression of SLC6A12 mRNA] |
CTD |
PMID:22053950 |
|
NCBI chr 4:154,585,386...154,603,750
Ensembl chr 4:154,585,500...154,603,750
|
|
G |
Slc6a20a |
solute carrier family 6 member 20a |
increases uptake |
ISO |
SLC6A20B protein results in increased uptake of Betaine |
CTD |
PMID:18845132 |
|
NCBI chr 8:123,282,325...123,322,609
Ensembl chr 8:123,281,472...123,322,573
|
|
G |
Slc6a9 |
solute carrier family 6 member 9 |
decreases expression |
EXP |
Betaine results in decreased expression of SLC6A9 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 5:131,374,562...131,408,733
Ensembl chr 5:131,374,542...131,408,728
|
|
G |
Snx10 |
sorting nexin 10 |
decreases expression |
EXP |
Betaine results in decreased expression of SNX10 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 4:80,612,648...80,677,005
Ensembl chr 4:80,612,669...80,676,996
|
|
G |
Socs2 |
suppressor of cytokine signaling 2 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of SOCS2 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 7:30,006,360...30,045,161
Ensembl chr 7:30,008,578...30,043,548
|
|
G |
Sostdc1 |
sclerostin domain containing 1 |
increases expression |
EXP |
Betaine results in increased expression of SOSTDC1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 6:53,051,336...53,055,510
Ensembl chr 6:53,051,354...53,055,579
|
|
G |
Spc25 |
SPC25 component of NDC80 kinetochore complex |
decreases expression |
EXP |
Betaine results in decreased expression of SPC25 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 3:53,930,013...53,988,940
Ensembl chr 3:53,975,704...53,988,959
|
|
G |
Ssr4 |
signal sequence receptor subunit 4 |
decreases expression |
EXP |
Betaine results in decreased expression of SSR4 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr X:151,524,191...151,528,218
Ensembl chr X:151,524,009...151,528,202
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
EXP |
Betaine promotes the reaction [Isoproterenol results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:25080425 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Stmn1 |
stathmin 1 |
decreases expression |
EXP |
Betaine results in decreased expression of STMN1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 5:146,680,757...146,687,154
Ensembl chr 5:146,681,436...146,687,154
|
|
G |
Stxbp1 |
syntaxin binding protein 1 |
decreases expression |
EXP |
Betaine results in decreased expression of STXBP1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 3:16,076,725...16,138,431
Ensembl chr 3:16,076,391...16,138,369
|
|
G |
Sult1e1 |
sulfotransferase family 1E member 1 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of SULT1E1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr14:20,422,324...20,439,562
Ensembl chr14:20,422,324...20,439,275
|
|
G |
Tgfb2 |
transforming growth factor, beta 2 |
increases expression |
EXP |
Betaine results in increased expression of TGFB2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr13:98,160,075...98,261,771
Ensembl chr13:98,160,087...98,261,405
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
Betaine inhibits the reaction [ATP7B protein mutant form results in increased expression of TNF mRNA] |
CTD |
PMID:22945834 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Trib2 |
tribbles pseudokinase 2 |
decreases expression |
EXP |
Betaine results in decreased expression of TRIB2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 6:38,545,971...38,570,349
Ensembl chr 6:38,545,975...38,569,370
|
|
G |
Ulk1 |
unc-51 like autophagy activating kinase 1 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of ULK1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr12:45,851,710...45,877,966
Ensembl chr12:45,851,710...45,877,966
|
|
G |
Upk3bl1 |
uroplakin 3B like 1 |
decreases expression |
EXP |
Betaine results in decreased expression of UPK3BL1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr12:20,610,353...20,616,366
Ensembl chr12:20,610,353...20,616,366
|
|
G |
Usp2 |
ubiquitin specific peptidase 2 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in increased expression of USP2 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 8:44,411,457...44,439,668
Ensembl chr 8:44,411,607...44,438,331
|
|
G |
Vnn1 |
vanin 1 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of VNN1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:21,537,084...21,547,395
Ensembl chr 1:21,537,094...21,547,395
|
|
G |
Wnk4 |
WNK lysine deficient protein kinase 4 |
decreases expression |
EXP |
Betaine results in decreased expression of WNK4 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr10:86,202,552...86,219,655
Ensembl chr10:86,188,812...86,231,829
|
|
G |
Ybx2 |
Y box binding protein 2 |
decreases expression |
EXP |
Betaine results in decreased expression of YBX2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr10:54,659,719...54,665,371
Ensembl chr10:54,659,719...54,665,371
|
|
|
G |
Adamts4 |
ADAM metallopeptidase with thrombospondin type 1 motif, 4 |
multiple interactions |
ISO |
stachydrine inhibits the reaction [IL1B protein results in increased secretion of ADAMTS4 protein] |
CTD |
PMID:32417162 |
|
NCBI chr13:83,670,556...83,680,045
Ensembl chr13:83,670,183...83,680,065
|
|
G |
Adamts5 |
ADAM metallopeptidase with thrombospondin type 1 motif, 5 |
multiple interactions |
ISO |
stachydrine inhibits the reaction [IL1B protein results in increased secretion of ADAMTS5 protein] |
CTD |
PMID:32417162 |
|
NCBI chr11:25,000,627...25,047,205
Ensembl chr11:25,000,637...25,047,205
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
stachydrine inhibits the reaction [IL1B protein results in increased expression of NOS2 protein]; stachydrine inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein]; stachydrine inhibits the reaction [IL1B protein results in increased phosphorylation of NFKBIA protein]; stachydrine inhibits the reaction [IL1B protein results in increased phosphorylation of RELA protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of ADAMTS4 protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of ADAMTS5 protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of IL6 protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of MMP13 protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of MMP3 protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of TNF protein] |
CTD |
PMID:32417162 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
stachydrine inhibits the reaction [IL1B protein results in increased secretion of IL6 protein] |
CTD |
PMID:32417162 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
multiple interactions |
ISO |
stachydrine inhibits the reaction [IL1B protein results in increased secretion of MMP13 protein] |
CTD |
PMID:32417162 |
|
NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
multiple interactions |
ISO |
stachydrine inhibits the reaction [IL1B protein results in increased secretion of MMP3 protein] |
CTD |
PMID:32417162 |
|
NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
stachydrine inhibits the reaction [IL1B protein results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:32417162 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
stachydrine inhibits the reaction [IL1B protein results in increased expression of NOS2 protein] |
CTD |
PMID:32417162 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
stachydrine inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein] |
CTD |
PMID:32417162 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
stachydrine inhibits the reaction [IL1B protein results in increased phosphorylation of RELA protein] |
CTD |
PMID:32417162 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
stachydrine inhibits the reaction [IL1B protein results in increased secretion of TNF protein] |
CTD |
PMID:32417162 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Acadl |
acyl-CoA dehydrogenase, long chain |
increases expression |
ISO |
3-(2,2,2-trimethylhydrazine)propionate results in increased expression of ACADL mRNA |
CTD |
PMID:32389661 |
|
NCBI chr 9:68,333,981...68,372,149
Ensembl chr 9:68,333,980...68,372,220
|
|
G |
Acadm |
acyl-CoA dehydrogenase medium chain |
decreases expression |
ISO |
3-(2,2,2-trimethylhydrazine)propionate results in decreased expression of ACADM mRNA |
CTD |
PMID:32389661 |
|
NCBI chr 2:242,858,865...242,883,036
Ensembl chr 2:242,858,865...242,883,147
|
|
G |
Acadvl |
acyl-CoA dehydrogenase, very long chain |
affects expression |
ISO |
3-(2,2,2-trimethylhydrazine)propionate affects the expression of ACADVL mRNA |
CTD |
PMID:32389661 |
|
NCBI chr10:54,732,875...54,738,102
Ensembl chr10:54,732,469...54,738,075
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
affects expression |
ISO |
3-(2,2,2-trimethylhydrazine)propionate affects the expression of ACOX1 mRNA |
CTD |
PMID:32389661 |
|
NCBI chr10:101,406,197...101,431,242
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Cpt1b |
carnitine palmitoyltransferase 1B |
decreases expression |
ISO |
3-(2,2,2-trimethylhydrazine)propionate results in decreased expression of CPT1B mRNA |
CTD |
PMID:32389661 |
|
NCBI chr 7:120,491,354...120,500,833
Ensembl chr 7:120,491,354...120,500,404
|
|
G |
Cpt1c |
carnitine palmitoyltransferase 1c |
decreases expression |
ISO |
3-(2,2,2-trimethylhydrazine)propionate results in decreased expression of CPT1C mRNA |
CTD |
PMID:32389661 |
|
NCBI chr 1:95,442,814...95,457,347
Ensembl chr 1:95,442,817...95,457,342
|
|
G |
Hk1 |
hexokinase 1 |
increases expression |
ISO |
3-(2,2,2-trimethylhydrazine)propionate results in increased expression of HK1 mRNA |
CTD |
PMID:32389661 |
|
NCBI chr20:30,230,488...30,332,161
Ensembl chr20:30,230,486...30,332,131
|
|
G |
Pdk1 |
pyruvate dehydrogenase kinase 1 |
increases expression |
ISO |
3-(2,2,2-trimethylhydrazine)propionate results in increased expression of PDK1 mRNA |
CTD |
PMID:32389661 |
|
NCBI chr 3:56,705,824...56,733,040
Ensembl chr 3:56,705,871...56,733,038
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
affects expression |
ISO |
3-(2,2,2-trimethylhydrazine)propionate affects the expression of PPARA mRNA |
CTD |
PMID:32389661 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
decreases expression |
EXP ISO |
3-(2,2,2-trimethylhydrazine)propionate results in decreased expression of PPARGC1A mRNA |
CTD |
PMID:27559315 PMID:32389661 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ppargc1b |
PPARG coactivator 1 beta |
affects expression |
EXP |
3-(2,2,2-trimethylhydrazine)propionate affects the expression of PPARGC1B mRNA |
CTD |
PMID:27559315 |
|
NCBI chr18:54,758,891...54,861,103
Ensembl chr18:54,758,902...54,861,194
|
|
G |
Slc22a5 |
solute carrier family 22 member 5 |
increases uptake |
EXP ISO |
SLC22A5 protein results in increased uptake of 3-(2,2,2-trimethylhydrazine)propionate |
CTD |
PMID:18981167 |
|
NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
increases expression |
ISO |
3-(2,2,2-trimethylhydrazine)propionate results in increased expression of SLC2A4 mRNA |
CTD |
PMID:32389661 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slc5a2 |
solute carrier family 5 member 2 |
affects expression |
ISO |
3-(2,2,2-trimethylhydrazine)propionate affects the expression of SLC5A2 mRNA |
CTD |
PMID:32389661 |
|
NCBI chr 1:182,847,185...182,853,309
Ensembl chr 1:182,847,106...182,853,306
|
|
G |
Tfam |
transcription factor A, mitochondrial |
decreases expression |
EXP |
3-(2,2,2-trimethylhydrazine)propionate results in decreased expression of TFAM mRNA |
CTD |
PMID:27559315 |
|
NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292
|
|
|
G |
Fxn |
frataxin |
increases expression |
ISO |
Molsidomine results in increased expression of FXN mRNA |
CTD |
PMID:23418481 |
|
NCBI chr 1:221,874,007...221,897,841
Ensembl chr 1:221,872,420...221,897,540
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
multiple interactions |
ISO |
Molsidomine inhibits the reaction [SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:21641380 |
|
NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678
|
|
G |
Slc22a3 |
solute carrier family 22 member 3 |
multiple interactions |
ISO |
Molsidomine inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:21641380 |
|
NCBI chr 1:48,235,476...48,324,617
Ensembl chr 1:48,235,476...48,324,612
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of ABCA1 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of ABCB4 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Bezafibrate] results in increased expression of ABCC2 mRNA |
CTD |
PMID:21549692 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcd1 |
ATP binding cassette subfamily D member 1 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of ABCD1 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of ABCD1 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr X:151,428,334...151,450,115
Ensembl chr X:151,428,578...151,450,115
|
|
G |
Abcd2 |
ATP binding cassette subfamily D member 2 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of ABCD2 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr 7:122,263,034...122,311,642
Ensembl chr 7:122,263,032...122,311,642
|
|
G |
Acaa1a |
acetyl-CoA acyltransferase 1A |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of ACAA1A mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of ACAA1A mRNA |
CTD |
PMID:23783067 |
|
NCBI chr 8:119,079,401...119,088,624
Ensembl chr 8:119,079,775...119,088,624
|
|
G |
Acaa1b |
acetyl-Coenzyme A acyltransferase 1B |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of ACAA1B mRNA |
CTD |
PMID:23783067 |
|
NCBI chr 8:118,872,996...118,881,852
Ensembl chr 8:118,872,997...118,881,825
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
increases expression decreases phosphorylation multiple interactions |
ISO |
Sodium Glutamate results in increased expression of ACACA mRNA; Sodium Glutamate results in increased expression of ACACA protein Sodium Glutamate results in decreased phosphorylation of ACACA protein 3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine affects the reaction [[Dietary Fats co-treated with Sodium Glutamate] affects the expression of ACACA mRNA]; [Dietary Fats co-treated with Sodium Glutamate] affects the expression of ACACA mRNA; SRT1720 inhibits the reaction [Sodium Glutamate results in increased expression of ACACA mRNA]; SRT1720 inhibits the reaction [Sodium Glutamate results in increased expression of ACACA protein] |
CTD |
PMID:19724016 PMID:22415589 PMID:26670228 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acacb |
acetyl-CoA carboxylase beta |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of ACACB mRNA |
CTD |
PMID:23783067 |
|
NCBI chr12:42,365,800...42,477,651
Ensembl chr12:42,366,548...42,457,655
|
|
G |
Acadl |
acyl-CoA dehydrogenase, long chain |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of ACADL mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 9:68,333,981...68,372,149
Ensembl chr 9:68,333,980...68,372,220
|
|
G |
Acadm |
acyl-CoA dehydrogenase medium chain |
multiple interactions increases expression |
ISO |
SRT1720 inhibits the reaction [Sodium Glutamate results in increased expression of ACADM mRNA] |
CTD |
PMID:19724016 |
|
NCBI chr 2:242,858,865...242,883,036
Ensembl chr 2:242,858,865...242,883,147
|
|
G |
Acads |
acyl-CoA dehydrogenase short chain |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of ACADS mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of ACADS mRNA; [Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of ACADS mRNA |
CTD |
PMID:19001666 PMID:23783067 |
|
NCBI chr12:41,493,650...41,502,897
Ensembl chr12:41,493,626...41,502,898
|
|
G |
Acadvl |
acyl-CoA dehydrogenase, very long chain |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of ACADVL mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of ACADVL mRNA |
CTD |
PMID:23783067 |
|
NCBI chr10:54,732,875...54,738,102
Ensembl chr10:54,732,469...54,738,075
|
|
G |
Ache |
acetylcholinesterase |
increases expression multiple interactions |
EXP |
Sodium Glutamate results in increased expression of ACHE mRNA Lycopene inhibits the reaction [Sodium Glutamate results in increased activity of ACHE protein] |
CTD |
PMID:20928830 PMID:26900785 |
|
NCBI chr12:19,407,359...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Acly |
ATP citrate lyase |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of ACLY mRNA |
CTD |
PMID:19001666 |
|
NCBI chr10:85,412,045...85,464,253
Ensembl chr10:85,412,049...85,463,320
|
|
G |
Aco1 |
aconitase 1 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of ACO1 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of ACO1 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr 5:55,259,841...55,315,872
Ensembl chr 5:55,259,827...55,316,391
|
|
G |
Acot1 |
acyl-CoA thioesterase 1 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of ACOT1 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr 6:103,636,173...103,644,167
Ensembl chr 6:103,636,041...103,644,163
|
|
G |
Acot12 |
acyl-CoA thioesterase 12 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of ACOT12 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 2:22,986,867...23,027,538
Ensembl chr 2:22,986,626...23,027,536
|
|
G |
Acot2 |
acyl-CoA thioesterase 2 |
increases expression multiple interactions |
ISO |
Sodium Glutamate results in increased expression of ACOT2 mRNA [Sodium Glutamate co-treated with High Fructose Corn Syrup] results in increased expression of ACOT2 mRNA |
CTD |
PMID:20111022 |
|
NCBI chr 6:103,611,744...103,619,404
Ensembl chr 6:103,611,544...103,619,245
|
|
G |
Acot4 |
acyl-CoA thioesterase 4 |
increases expression multiple interactions |
ISO |
Sodium Glutamate results in increased expression of ACOT4 mRNA [Sodium Glutamate co-treated with High Fructose Corn Syrup] results in increased expression of ACOT4 mRNA |
CTD |
PMID:20111022 |
|
NCBI chr 6:103,668,699...103,674,037
Ensembl chr 6:103,668,753...103,673,917
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
multiple interactions |
ISO EXP |
[Sodium Glutamate co-treated with Bezafibrate] results in increased expression of ACOX1 mRNA [Taurine co-treated with Sodium Glutamate] results in increased expression of ACOX1 mRNA |
CTD |
PMID:21549692 PMID:26092479 |
|
NCBI chr10:101,406,197...101,431,242
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Acr |
acrosin |
increases expression |
EXP |
Sodium Glutamate results in increased expression of ACR mRNA |
CTD |
PMID:20928830 |
|
NCBI chr 7:120,636,581...120,644,474
Ensembl chr 7:120,638,321...120,644,474
|
|
G |
Acsbg1 |
acyl-CoA synthetase bubblegum family member 1 |
increases expression |
EXP |
Sodium Glutamate results in increased expression of ACSBG1 mRNA |
CTD |
PMID:20928830 |
|
NCBI chr 8:54,991,294...55,047,276
Ensembl chr 8:54,991,296...55,047,391
|
|
G |
Acsf2 |
acyl-CoA synthetase family member 2 |
multiple interactions |
ISO |
[Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of ACSF2 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr10:79,504,510...79,546,714
Ensembl chr10:79,504,511...79,546,673
|
|
G |
Acsl3 |
acyl-CoA synthetase long-chain family member 3 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of ACSL3 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 9:80,140,996...80,164,636
Ensembl chr 9:80,115,112...80,164,627
|
|
G |
Acvr2b |
activin A receptor type 2B |
increases expression |
EXP |
Sodium Glutamate results in increased expression of ACVR2B mRNA |
CTD |
PMID:20928830 |
|
NCBI chr 8:119,138,901...119,178,477
Ensembl chr 8:119,138,812...119,170,458
|
|
G |
Adam5 |
ADAM metallopeptidase domain 5 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of ADAM5 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr16:67,223,095...67,298,733
Ensembl chr16:67,223,143...67,298,737
|
|
G |
Adamts7 |
ADAM metallopeptidase with thrombospondin type 1 motif, 7 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of ADAMTS7 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 8:90,704,727...90,744,331
Ensembl chr 8:90,704,727...90,744,328
|
|
G |
Adamtsl3 |
ADAMTS-like 3 |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of ADAMTSL3 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 1:136,288,793...136,596,986
Ensembl chr 1:136,288,793...136,596,986
|
|
G |
Adcy5 |
adenylate cyclase 5 |
increases expression |
EXP |
Sodium Glutamate results in increased expression of ADCY5 mRNA |
CTD |
PMID:20928830 |
|
NCBI chr11:65,471,612...65,618,877
Ensembl chr11:65,471,612...65,618,974
|
|
G |
Adgre1 |
adhesion G protein-coupled receptor E1 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of ADGRE1 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr 9:2,242,476...2,398,000
Ensembl chr 9:2,242,474...2,398,000
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions decreases expression |
ISO |
[Sodium Glutamate co-treated with Pioglitazone] results in increased expression of ADIPOQ protein; [Sodium Glutamate co-treated with Plant Extracts] results in decreased expression of ADIPOQ mRNA; Bezafibrate inhibits the reaction [Sodium Glutamate results in decreased expression of ADIPOQ protein]; fructooligosaccharide inhibits the reaction [Sodium Glutamate results in decreased expression of ADIPOQ protein] |
CTD |
PMID:21549692 PMID:27918843 PMID:32103741 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Adora1 |
adenosine A1 receptor |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of ADORA1 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr13:45,658,872...45,695,821
Ensembl chr13:45,658,872...45,695,801
|
|
G |
Adra1a |
adrenoceptor alpha 1A |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of ADRA1A mRNA |
CTD |
PMID:19001666 |
|
NCBI chr15:40,830,125...40,935,902
Ensembl chr15:40,832,534...40,927,500
|
|
G |
Adra1d |
adrenoceptor alpha 1D |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of ADRA1D mRNA |
CTD |
PMID:20111022 |
|
NCBI chr 3:118,793,356...118,809,354
Ensembl chr 3:118,793,346...118,809,354
|
|
G |
Agrp |
agouti related neuropeptide |
decreases expression |
EXP |
Sodium Glutamate results in decreased expression of AGRP mRNA |
CTD |
PMID:19151514 |
|
NCBI chr19:33,447,992...33,523,068
Ensembl chr19:33,447,992...33,449,584
|
|
G |
Ahr |
aryl hydrocarbon receptor |
increases expression |
ISO |
Sodium Glutamate results in increased expression of AHR mRNA |
CTD |
PMID:19001666 PMID:22078008 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Aifm3 |
apoptosis inducing factor, mitochondria associated 3 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of AIFM3 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr11:83,504,859...83,523,630
Ensembl chr11:83,504,861...83,521,248
|
|
G |
Akr1a1 |
aldo-keto reductase family 1 member A1 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of AKR1A1 mRNA; Sodium Glutamate results in increased expression of AKR1A1 protein |
CTD |
PMID:25473020 |
|
NCBI chr 5:130,092,945...130,130,277
Ensembl chr 5:130,092,732...130,113,674
|
|
G |
Akr1c1 |
aldo-keto reductase family 1, member C1 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of AKR1C6 mRNA |
CTD |
PMID:25473020 |
|
NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation multiple interactions |
ISO |
Sodium Glutamate results in decreased phosphorylation of AKT1 protein Tea inhibits the reaction [Sodium Glutamate results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:29679905 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
multiple interactions increases expression |
ISO |
[Sodium Glutamate co-treated with High Fructose Corn Syrup] results in increased expression of ALDH1A1 mRNA Sodium Glutamate results in increased expression of ALDH1A1 mRNA |
CTD |
PMID:20111022 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Aldh1a3 |
aldehyde dehydrogenase 1 family, member A3 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of ALDH1A3 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 1:119,982,272...120,017,416
Ensembl chr 1:119,982,277...120,017,436
|
|
G |
Aldh1l2 |
aldehyde dehydrogenase 1 family, member L2 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with High Fructose Corn Syrup] results in increased expression of ALDH1L2 mRNA |
CTD |
PMID:20111022 |
|
NCBI chr 7:20,254,196...20,305,793
Ensembl chr 7:20,254,233...20,305,776
|
|
G |
Aldh3a1 |
aldehyde dehydrogenase 3 family, member A1 |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of ALDH3A1 mRNA |
CTD |
PMID:20111022 |
|
NCBI chr10:45,892,993...45,902,680
Ensembl chr10:45,892,924...45,902,681
|
|
G |
Alg6 |
ALG6, alpha-1,3-glucosyltransferase |
multiple interactions |
ISO |
[Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of ALG6 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 5:114,404,972...114,454,440
Ensembl chr 5:114,405,010...114,454,439
|
|
G |
Alox15 |
arachidonate 15-lipoxygenase |
increases expression multiple interactions |
ISO |
Sodium Glutamate results in increased expression of ALOX15 mRNA [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of ALOX15 mRNA; [Sodium Glutamate co-treated with High Fructose Corn Syrup] results in increased expression of ALOX15 mRNA |
CTD |
PMID:20111022 PMID:23783067 |
|
NCBI chr10:55,060,169...55,068,885
Ensembl chr10:55,060,412...55,068,874
|
|
G |
Ambra1 |
autophagy and beclin 1 regulator 1 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of AMBRA1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 3:77,700,936...77,890,221
Ensembl chr 3:77,700,936...77,890,221
|
|
G |
Anxa1 |
annexin A1 |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of ANXA1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343
|
|
G |
Ap1m2 |
adaptor related protein complex 1 subunit mu 2 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of AP1M2 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 8:19,838,579...19,856,560
Ensembl chr 8:19,838,580...19,856,482
|
|
G |
Apbb1 |
amyloid beta precursor protein binding family B member 1 |
increases expression |
EXP |
Sodium Glutamate results in increased expression of APBB1 mRNA |
CTD |
PMID:20928830 |
|
NCBI chr 1:159,896,889...159,920,505
Ensembl chr 1:159,896,880...159,920,627
|
|
G |
Apmap |
adipocyte plasma membrane associated protein |
multiple interactions |
ISO |
[Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of APMAP mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 3:139,409,020...139,437,296
Ensembl chr 3:139,409,022...139,437,341
|
|
G |
Apoc2 |
apolipoprotein C2 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with High Fructose Corn Syrup] results in increased expression of APOC2 mRNA |
CTD |
PMID:20111022 |
|
NCBI chr 1:79,329,429...79,334,397
Ensembl chr 1:79,329,428...79,334,476
|
|
G |
Apod |
apolipoprotein D |
multiple interactions increases expression |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in decreased expression of APOD mRNA Sodium Glutamate results in increased expression of APOD mRNA |
CTD |
PMID:19001666 PMID:20111022 |
|
NCBI chr11:69,431,261...69,452,306
Ensembl chr11:69,431,260...69,452,305
|
|
G |
Apoe |
apolipoprotein E |
increases expression multiple interactions |
EXP ISO |
Sodium Glutamate results in increased expression of APOE mRNA 6-methyl-2-(phenylethynyl)pyridine inhibits the reaction [Sodium Glutamate results in increased expression of APOE mRNA] Sodium Glutamate results in increased expression of APOE mRNA; Sodium Glutamate results in increased expression of APOE protein |
CTD |
PMID:31981724 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Arap3 |
ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 3 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of ARAP3 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr18:29,806,214...29,834,217
Ensembl chr18:29,807,536...29,833,555
|
|
G |
Arc |
activity-regulated cytoskeleton-associated protein |
multiple interactions |
ISO |
[Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of ARC mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 7:106,555,968...106,559,697
Ensembl chr 7:106,555,785...106,559,378
|
|
G |
Arg2 |
arginase 2 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of ARG2 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 6:97,936,002...97,961,379
Ensembl chr 6:97,936,002...97,961,378
|
|
G |
Arhgef1 |
Rho guanine nucleotide exchange factor 1 |
increases expression |
EXP |
Sodium Glutamate results in increased expression of ARHGEF1 mRNA |
CTD |
PMID:20928830 |
|
NCBI chr 1:80,499,026...80,520,954
Ensembl chr 1:80,499,131...80,520,953
|
|
G |
Arsb |
arylsulfatase B |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of ARSB mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 2:25,002,210...25,162,675
Ensembl chr 2:25,002,346...25,162,671
|
|
G |
Atp1a3 |
ATPase Na+/K+ transporting subunit alpha 3 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of ATP1A3 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 1:80,572,790...80,601,936
Ensembl chr 1:80,572,796...80,601,918
|
|
G |
Atp2b3 |
ATPase plasma membrane Ca2+ transporting 3 |
increases expression |
EXP |
Sodium Glutamate results in increased expression of ATP2B3 mRNA |
CTD |
PMID:20928830 |
|
NCBI chr X:151,216,483...151,289,069
Ensembl chr X:151,216,507...151,286,775
|
|
G |
Atp7b |
ATPase copper transporting beta |
increases expression |
ISO |
Sodium Glutamate results in increased expression of ATP7B mRNA |
CTD |
PMID:22078008 |
|
NCBI chr16:69,952,286...70,024,404
Ensembl chr16:69,951,778...70,023,636
|
|
G |
Axin1 |
axin 1 |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of AXIN1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr10:15,163,684...15,215,615
Ensembl chr10:15,163,684...15,215,615
|
|
G |
Bambi |
BMP and activin membrane-bound inhibitor |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of BAMBI mRNA |
CTD |
PMID:22078008 |
|
NCBI chr17:54,121,251...54,125,816
Ensembl chr17:54,121,255...54,126,060
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
EXP ISO |
Sodium Glutamate results in increased expression of BAX mRNA [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of BAX mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of BAX mRNA Lycopene inhibits the reaction [Sodium Glutamate results in increased expression of BAX mRNA] |
CTD |
PMID:23783067 PMID:26900785 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bccip |
BRCA2 and CDKN1A interacting protein |
multiple interactions increases expression |
ISO |
[Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of BCCIP mRNA Sodium Glutamate results in increased expression of BCCIP mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 1:188,512,544...188,524,957
Ensembl chr 1:188,512,367...188,524,958
|
|
G |
Bche |
butyrylcholinesterase |
increases activity multiple interactions |
EXP |
Sodium Glutamate results in increased activity of BCHE protein Lycopene inhibits the reaction [Sodium Glutamate results in increased activity of BCHE protein] |
CTD |
PMID:26900785 |
|
NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression multiple interactions decreases expression |
ISO EXP |
Sodium Glutamate results in increased expression of BCL2 mRNA [Homocysteine co-treated with Sodium Glutamate] affects the expression of BCL2 mRNA; [Homocysteine co-treated with Sodium Glutamate] affects the expression of BCL2 protein; Folic Acid affects the reaction [[Homocysteine co-treated with Sodium Glutamate] affects the expression of BCL2 mRNA]; Folic Acid affects the reaction [[Homocysteine co-treated with Sodium Glutamate] affects the expression of BCL2 protein]; Lycopene inhibits the reaction [Sodium Glutamate results in decreased expression of BCL2 mRNA] SB 203580 inhibits the reaction [Sodium Glutamate results in increased expression of BCL2 mRNA] |
CTD |
PMID:16782274 PMID:22169520 PMID:26900785 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
increases expression multiple interactions |
ISO |
Sodium Glutamate results in increased expression of BCL2L11 mRNA [Sodium Glutamate co-treated with Trans Fatty Acids] results in decreased expression of BCL2L11 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Bend3 |
BEN domain containing 3 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of BEND3 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr20:46,980,246...47,017,059
Ensembl chr20:46,979,831...47,014,671
|
|
G |
Bin3 |
bridging integrator 3 |
multiple interactions |
ISO |
[Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of BIN3 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr15:45,173,725...45,212,607
Ensembl chr15:45,173,732...45,212,604
|
|
G |
Bmi1 |
BMI1 proto-oncogene, polycomb ring finger |
increases expression multiple interactions |
ISO |
Sodium Glutamate results in increased expression of BMI1 mRNA [Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of BMI1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr17:81,332,175...81,341,625
Ensembl chr17:81,332,214...81,388,690
|
|
G |
Bnip5 |
BCL2 interacting protein 5 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of BNIP5 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr20:6,957,736...6,975,062
Ensembl chr20:6,956,201...6,975,091
|
|
G |
Bop1 |
BOP1 ribosomal biogenesis factor |
increases expression |
ISO |
Sodium Glutamate results in increased expression of BOP1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 7:108,172,062...108,195,875
Ensembl chr 7:108,172,066...108,195,931
|
|
G |
Brsk2 |
BR serine/threonine kinase 2 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of BRSK2 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 1:197,035,522...197,088,624
Ensembl chr 1:197,035,633...197,088,092
|
|
G |
Bzw2 |
basic leucine zipper and W2 domains 2 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of BZW2 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 6:52,828,069...52,888,599
Ensembl chr 6:52,827,661...52,888,628
|
|
G |
C1qtnf1 |
C1q and TNF related 1 |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of C1QTNF1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr10:103,660,319...103,681,662
Ensembl chr10:103,660,327...103,681,660
|
|
G |
Cabp2 |
calcium binding protein 2 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CABP2 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of CABP2 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr 1:201,374,649...201,380,469
Ensembl chr 1:201,375,276...201,380,469
|
|
G |
Cacna1a |
calcium voltage-gated channel subunit alpha1 A |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CACNA1A mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of CACNA1A mRNA |
CTD |
PMID:23783067 |
|
NCBI chr19:23,520,741...23,819,971
Ensembl chr19:23,520,741...23,823,225
|
|
G |
Cacna1i |
calcium voltage-gated channel subunit alpha1 I |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CACNA1I mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of CACNA1I mRNA |
CTD |
PMID:23783067 |
|
NCBI chr 7:111,835,996...111,947,418
Ensembl chr 7:111,836,012...111,944,688
|
|
G |
Cacna2d4 |
calcium voltage-gated channel auxiliary subunit alpha2delta 4 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CACNA2D4 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of CACNA2D4 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr 4:152,408,657...152,524,614
Ensembl chr 4:152,408,657...152,521,268
|
|
G |
Cacnb2 |
calcium voltage-gated channel auxiliary subunit beta 2 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CACNB2 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of CACNB2 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr17:77,564,630...77,910,000
Ensembl chr17:77,564,460...77,909,106
|
|
G |
Cacng4 |
calcium voltage-gated channel auxiliary subunit gamma 4 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CACNG4 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of CACNG4 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr10:92,686,100...92,745,601
Ensembl chr10:92,683,761...92,746,126
|
|
G |
Cacng8 |
calcium voltage-gated channel auxiliary subunit gamma 8 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CACNG8 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of CACNG8 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr 1:65,755,334...65,775,567
Ensembl chr 1:65,755,334...65,779,089
|
|
G |
Calhm2 |
calcium homeostasis modulator family member 2 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CALHM2 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of CALHM2 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr 1:246,022,324...246,028,050
Ensembl chr 1:246,022,324...246,028,218
|
|
G |
Calr |
calreticulin |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of CALR mRNA |
CTD |
PMID:22078008 |
|
NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
|
|
G |
Calr3 |
calreticulin 3 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CALR3 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of CALR3 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr16:17,396,064...17,423,166
Ensembl chr16:17,396,247...17,423,015
|
|
G |
Camk2a |
calcium/calmodulin-dependent protein kinase II alpha |
increases expression |
EXP |
Sodium Glutamate results in increased expression of CAMK2A mRNA |
CTD |
PMID:20928830 |
|
NCBI chr18:54,378,642...54,441,120
Ensembl chr18:54,378,784...54,438,994
|
|
G |
Camk2b |
calcium/calmodulin-dependent protein kinase II beta |
increases expression |
ISO |
Sodium Glutamate results in increased expression of CAMK2B mRNA |
CTD |
PMID:22078008 |
|
NCBI chr14:80,845,206...80,934,172
Ensembl chr14:80,845,238...80,933,994
|
|
G |
Camlg |
calcium modulating ligand |
decreases expression |
EXP |
Sodium Glutamate results in decreased expression of CAMLG mRNA |
CTD |
PMID:20928830 |
|
NCBI chr17:8,992,697...9,003,576
Ensembl chr17:8,992,696...9,003,552
|
|
G |
Cant1 |
calcium activated nucleotidase 1 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CANT1 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of CANT1 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr10:103,637,079...103,650,240
Ensembl chr10:103,531,504...103,650,109
|
|
G |
Caps2 |
calcyphosine 2 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of CAPS2 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 7:47,580,636...47,641,598
Ensembl chr 7:47,581,137...47,639,229
|
|
G |
Car2 |
carbonic anhydrase 2 |
decreases expression |
EXP |
Sodium Glutamate results in decreased expression of CAR2 mRNA |
CTD |
PMID:31569818 |
|
NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818
|
|
G |
Car5b |
carbonic anhydrase 5B |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of CAR5B mRNA |
CTD |
PMID:22078008 |
|
NCBI chr X:30,474,697...30,534,797
Ensembl chr X:30,474,784...30,533,837
|
|
G |
Casp6 |
caspase 6 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with High Fructose Corn Syrup] results in increased expression of CASP6 mRNA |
CTD |
PMID:20111022 |
|
NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CASP9 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of CASP9 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
increases expression increases activity multiple interactions decreases activity decreases expression |
ISO EXP |
Sodium Glutamate results in increased expression of CAT mRNA; Sodium Glutamate results in increased expression of CAT protein Sodium Glutamate results in increased activity of CAT protein Lycopene inhibits the reaction [Sodium Glutamate results in increased activity of CAT protein]; Lycopene inhibits the reaction [Sodium Glutamate results in increased expression of CAT mRNA] [Plant Extracts co-treated with Sodium Glutamate] results in increased activity of CAT protein; Sodium Glutamate results in increased expression of and results in decreased activity of CAT protein; SRT1720 inhibits the reaction [Sodium Glutamate results in increased expression of CAT mRNA]; SRT1720 inhibits the reaction [Sodium Glutamate results in increased expression of CAT protein]; Tea inhibits the reaction [Sodium Glutamate results in decreased activity of CAT protein] Sodium Glutamate results in decreased expression of CAT mRNA |
CTD |
PMID:19724016 PMID:25473020 PMID:26319613 PMID:26900785 PMID:29679905 PMID:30733785 More...
|
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Catsper1 |
cation channel, sperm associated 1 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of CATSPER1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 1:202,643,009...202,652,059
Ensembl chr 1:202,643,038...202,651,824
|
|
G |
Catsper2 |
cation channel, sperm associated 2 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of CATSPER2 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 3:108,368,654...108,389,380
Ensembl chr 3:108,368,668...108,388,050
|
|
G |
Cbr1 |
carbonyl reductase 1 |
increases activity |
ISO |
Sodium Glutamate results in increased activity of CBR1 protein |
CTD |
PMID:25473020 |
|
NCBI chr11:32,860,618...32,862,981
Ensembl chr11:32,908,950...32,911,393 Ensembl chr11:32,908,950...32,911,393
|
|
G |
Cbr1l1 |
carbonyl reductase 1 like 1 |
increases activity |
ISO |
Sodium Glutamate results in increased activity of CBR1 protein |
CTD |
PMID:25473020 |
|
NCBI chr11:32,876,563...32,884,234
|
|
G |
Ccdc138 |
coiled-coil domain containing 138 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of CCDC138 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr20:26,493,624...26,572,367
Ensembl chr20:26,495,235...26,572,376
|
|
G |
Ccdc30 |
coiled-coil domain containing 30 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of CCDC30 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 5:132,926,767...133,019,635
Ensembl chr 5:132,926,615...133,019,659
|
|
G |
Ccdc39 |
coiled-coil domain containing 39 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of CCDC39 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 2:116,665,261...116,703,364
Ensembl chr 2:116,665,261...116,703,350
|
|
G |
Ccdc60 |
coiled-coil domain containing 60 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of CCDC60 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr12:40,314,687...40,480,338
Ensembl chr12:40,314,713...40,480,225
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression multiple interactions decreases expression |
ISO |
Sodium Glutamate results in increased expression of CCL2 mRNA; Sodium Glutamate results in increased expression of CCL2 protein [Fats, Unsaturated co-treated with Sodium Glutamate] results in increased expression of CCL2 protein; [Sodium Glutamate co-treated with Aspartame] inhibits the reaction [Fats, Unsaturated results in increased expression of CCL2 protein]; SRT1720 inhibits the reaction [Sodium Glutamate results in increased expression of CCL2 mRNA]; SRT1720 inhibits the reaction [Sodium Glutamate results in increased expression of CCL2 protein] Sodium Glutamate results in decreased expression of CCL2 mRNA |
CTD |
PMID:19724016 PMID:20111022 PMID:23783067 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl21 |
C-C motif chemokine ligand 21 |
multiple interactions increases expression |
ISO |
[Sodium Glutamate co-treated with High Fructose Corn Syrup] results in decreased expression of CCL21A mRNA Sodium Glutamate results in increased expression of CCL21A mRNA |
CTD |
PMID:20111022 |
|
NCBI chr 5:56,980,557...56,981,661
Ensembl chr 5:56,980,558...56,981,686
|
|
G |
Ccnd2 |
cyclin D2 |
multiple interactions affects expression |
ISO EXP |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of CCND2 mRNA Sodium Glutamate affects the expression of CCND2 mRNA |
CTD |
PMID:19001666 PMID:28954212 |
|
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Ccnd3 |
cyclin D3 |
increases expression decreases expression multiple interactions |
ISO |
Sodium Glutamate results in increased expression of CCND3 mRNA Sodium Glutamate results in decreased expression of CCND3 mRNA [Sodium Glutamate co-treated with High Fructose Corn Syrup] results in increased expression of CCND3 mRNA |
CTD |
PMID:20111022 PMID:22078008 |
|
NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
|
|
G |
Ccng1 |
cyclin G1 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of CCNG1 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641
|
|
G |
Cd80 |
Cd80 molecule |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in decreased expression of CD80 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr11:62,254,543...62,293,414
Ensembl chr11:62,254,624...62,292,030
|
|
G |
Cd81 |
Cd81 molecule |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with High Fructose Corn Syrup] results in increased expression of CD81 mRNA |
CTD |
PMID:20111022 |
|
NCBI chr 1:198,235,861...198,251,660
Ensembl chr 1:198,241,484...198,251,660
|
|
G |
Cd86 |
CD86 molecule |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in decreased expression of CD86 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Cdcp2 |
CUB domain containing protein 2 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of CDCP2 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 5:121,877,581...121,894,203
Ensembl chr 5:121,877,581...121,894,203
|
|
G |
Cdh1 |
cadherin 1 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of CDH1 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdk5 |
cyclin-dependent kinase 5 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of CDK5 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 4:10,754,682...10,760,110
Ensembl chr 4:10,754,687...10,760,112
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] affects the expression of CDKN1A mRNA |
CTD |
PMID:19001666 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CDKN1B mRNA |
CTD |
PMID:23783067 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn1c |
cyclin-dependent kinase inhibitor 1C |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in decreased expression of CDKN1C mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 1:198,655,394...198,658,097
Ensembl chr 1:198,655,407...198,658,048
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
decreases expression increases expression |
EXP ISO |
Sodium Glutamate results in decreased expression of CDKN2A mRNA; Sodium Glutamate results in decreased expression of CDKN2A protein Sodium Glutamate results in increased expression of CDKN2A mRNA |
CTD |
PMID:22078008 PMID:28954212 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Cdkn2b |
cyclin-dependent kinase inhibitor 2B |
multiple interactions increases expression |
ISO EXP |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of CDKN2B mRNA Sodium Glutamate results in increased expression of CDKN2B mRNA |
CTD |
PMID:19001666 PMID:28954212 |
|
NCBI chr 5:104,009,839...104,019,082
Ensembl chr 5:104,010,680...104,019,050
|
|
G |
Cdkn2d |
cyclin dependent kinase inhibitor 2D |
decreases expression |
EXP |
Sodium Glutamate results in decreased expression of CDKN2D mRNA |
CTD |
PMID:28954212 |
|
NCBI chr 8:19,831,874...19,834,640
Ensembl chr 8:19,831,866...19,834,674
|
|
G |
Cds1 |
CDP-diacylglycerol synthase 1 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of CDS1 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr14:7,820,328...7,882,943
Ensembl chr14:7,820,351...7,882,681
|
|
G |
Cep76 |
centrosomal protein 76 |
multiple interactions |
ISO |
[Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of CEP76 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr18:61,174,514...61,208,512
Ensembl chr18:61,178,310...61,208,504
|
|
G |
Cfd |
complement factor D |
decreases activity decreases expression multiple interactions |
ISO |
Sodium Glutamate results in decreased activity of CFD protein Sodium Glutamate results in decreased expression of CFD mRNA; Sodium Glutamate results in decreased expression of CFD protein [Caffeine co-treated with Ephedrine] affects the reaction [Sodium Glutamate results in decreased expression of CFD mRNA]; [Caffeine co-treated with Ephedrine] affects the reaction [Sodium Glutamate results in decreased expression of CFD protein]; [Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of CFD mRNA |
CTD |
PMID:2307116 PMID:2734615 PMID:2798420 PMID:3299706 PMID:7961801 PMID:19001666 More...
|
|
NCBI chr 7:9,813,148...9,814,871
Ensembl chr 7:9,813,150...9,815,053
|
|
G |
Cga |
glycoprotein hormones, alpha polypeptide |
multiple interactions |
EXP |
Sodium Glutamate inhibits the reaction [CGA protein results in increased secretion of 7-hydroxyprogesterone]; Sodium Glutamate inhibits the reaction [CGA protein results in increased secretion of Androstenedione] |
CTD |
PMID:14657608 |
|
NCBI chr 5:49,486,915...49,499,192
Ensembl chr 5:49,487,068...49,499,191
|
|
G |
Cherp |
calcium homeostasis endoplasmic reticulum protein |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CHERP mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of CHERP mRNA |
CTD |
PMID:23783067 |
|
NCBI chr16:17,367,455...17,380,507
Ensembl chr16:17,367,455...17,380,507
|
|
G |
Chmp5 |
charged multivesicular body protein 5 |
multiple interactions |
ISO |
[Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of CHMP5 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 5:56,081,385...56,098,529
Ensembl chr 5:56,081,343...56,098,529
|
|
G |
Chrnb3 |
cholinergic receptor nicotinic beta 3 subunit |
increases expression |
ISO |
Sodium Glutamate results in increased expression of CHRNB3 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr16:64,713,438...64,751,360
Ensembl chr16:64,714,169...64,751,360
|
|
G |
Chst1 |
carbohydrate sulfotransferase 1 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of CHST1 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 3:78,552,059...78,574,736
Ensembl chr 3:78,548,525...78,574,883
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
increases phosphorylation decreases expression multiple interactions |
ISO EXP |
Sodium Glutamate results in increased phosphorylation of CHUK protein Sodium Glutamate results in decreased expression of CHUK mRNA Atorvastatin inhibits the reaction [Sodium Glutamate results in increased phosphorylation of CHUK protein] |
CTD |
PMID:19800637 PMID:28954212 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Ciao2a |
cytosolic iron-sulfur assembly component 2A |
multiple interactions |
ISO |
[Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of CIAO2A mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 8:66,670,533...66,682,455
Ensembl chr 8:66,670,483...66,682,455
|
|
G |
Ciart |
circadian associated repressor of transcription |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of CIART mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 2:183,419,819...183,424,845
Ensembl chr 2:183,419,819...183,423,313
|
|
G |
Cidea |
cell death-inducing DFFA-like effector a |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of CIDEA mRNA |
CTD |
PMID:19001666 |
|
NCBI chr18:60,894,917...60,920,485
Ensembl chr18:60,894,874...60,920,481
|
|
G |
Cidec |
cell death-inducing DFFA-like effector c |
multiple interactions increases expression |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of CIDEC mRNA Sodium Glutamate results in increased expression of CIDEC mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 4:146,569,288...146,582,173
Ensembl chr 4:146,569,289...146,582,173
|
|
G |
Ckb |
creatine kinase B |
multiple interactions increases activity |
EXP |
Lycopene inhibits the reaction [Sodium Glutamate results in increased activity of CKB protein] |
CTD |
PMID:26900785 |
|
NCBI chr 6:130,729,420...130,732,301
Ensembl chr 6:130,729,423...130,732,315
|
|
G |
Clspn |
claspin |
increases expression |
ISO |
Sodium Glutamate results in increased expression of CLSPN mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 5:138,850,119...138,885,037
Ensembl chr 5:138,850,128...138,885,034
|
|
G |
Clstn3 |
calsyntenin 3 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of CLSTN3 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 4:157,331,494...157,364,769
Ensembl chr 4:157,331,494...157,364,769
|
|
G |
Cmc1 |
C-x(9)-C motif containing 1 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CMC1 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of CMC1 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr 8:117,798,036...117,900,458
Ensembl chr 8:117,798,945...117,900,462
|
|
G |
Cmklr1 |
chemerin chemokine-like receptor 1 |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of CMKLR1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr12:42,974,462...43,027,321
Ensembl chr12:42,974,410...43,028,129
|
|
G |
Cnih4 |
cornichon family AMPA receptor auxiliary protein 4 |
multiple interactions |
ISO |
[Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of CNIH4 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr13:92,910,315...92,926,428
Ensembl chr13:92,910,315...92,927,853
|
|
G |
Cnnm3 |
cyclin and CBS domain divalent metal cation transport mediator 3 |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of CNNM3 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 9:38,755,374...38,770,740
Ensembl chr 9:38,755,390...38,770,740
|
|
G |
Coa7 |
cytochrome c oxidase assembly factor 7 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of COA7 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 5:123,069,356...123,080,942
Ensembl chr 5:123,069,371...123,080,199
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
decreases expression |
EXP |
Sodium Glutamate results in decreased expression of COL1A1 mRNA |
CTD |
PMID:28954212 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of COL3A1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
|
|
G |
Comp |
cartilage oligomeric matrix protein |
multiple interactions decreases expression |
ISO |
[Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of COMP mRNA Sodium Glutamate results in decreased expression of COMP mRNA |
CTD |
PMID:22078008 |
|
NCBI chr16:19,047,206...19,055,584
Ensembl chr16:19,047,207...19,055,845
|
|
G |
Comt |
catechol-O-methyltransferase |
increases expression |
ISO |
Sodium Glutamate results in increased expression of COMT mRNA |
CTD |
PMID:22078008 |
|
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
|
|
G |
Cops3 |
COP9 signalosome subunit 3 |
increases expression multiple interactions |
ISO |
Sodium Glutamate results in increased expression of COPS3 mRNA [Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of COPS3 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr10:44,618,115...44,652,807
Ensembl chr10:44,618,115...44,641,597
|
|
G |
Coq10b |
coenzyme Q10B |
multiple interactions |
ISO |
[Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of COQ10B mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 9:56,553,751...56,573,671
Ensembl chr 9:56,553,758...56,573,663
|
|
G |
Cotl1 |
coactosin-like F-actin binding protein 1 |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of COTL1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr19:47,871,689...47,906,010
Ensembl chr19:47,871,694...47,911,689
|
|
G |
Cox11 |
cytochrome c oxidase copper chaperone COX11 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of COX11 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of COX11 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr10:75,458,735...75,465,322
Ensembl chr10:75,458,749...75,465,322
|
|
G |
Cox4i2 |
cytochrome c oxidase subunit 4i2 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with High Fructose Corn Syrup] results in increased expression of COX4I2 mRNA |
CTD |
PMID:20111022 |
|
NCBI chr 3:141,228,443...141,239,337
Ensembl chr 3:141,228,443...141,239,331
|
|
G |
Cox7a1 |
cytochrome c oxidase subunit 7A1 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of COX7A1 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of COX7A1 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr 1:85,422,162...85,447,530
Ensembl chr 1:85,441,871...85,445,151
|
|
G |
Cox7a2l |
cytochrome c oxidase subunit 7A2 like |
increases expression |
ISO |
Sodium Glutamate results in increased expression of COX7A2L mRNA |
CTD |
PMID:20111022 |
|
NCBI chr 6:11,184,284...11,198,287
Ensembl chr 6:11,184,285...11,198,273
|
|
G |
Cpne2 |
copine 2 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of CPNE2 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr19:10,434,277...10,472,146
Ensembl chr19:10,434,277...10,471,820
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions decreases expression |
ISO EXP |
[Sodium Glutamate co-treated with Bezafibrate] results in increased expression of CPT1A mRNA Sodium Glutamate results in decreased expression of CPT1A mRNA Taurine inhibits the reaction [Sodium Glutamate results in decreased expression of CPT1A mRNA] |
CTD |
PMID:21549692 PMID:26092479 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Cpt1b |
carnitine palmitoyltransferase 1B |
increases expression multiple interactions |
ISO |
Sodium Glutamate results in increased expression of CPT1B mRNA [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CPT1B mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of CPT1B mRNA; [Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of CPT1B mRNA; SRT1720 inhibits the reaction [Sodium Glutamate results in increased expression of CPT1B mRNA] |
CTD |
PMID:19001666 PMID:19724016 PMID:23783067 |
|
NCBI chr 7:120,491,354...120,500,833
Ensembl chr 7:120,491,354...120,500,404
|
|
G |
Cpt1c |
carnitine palmitoyltransferase 1c |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CPT1C mRNA |
CTD |
PMID:23783067 |
|
NCBI chr 1:95,442,814...95,457,347
Ensembl chr 1:95,442,817...95,457,342
|
|
G |
Cpt2 |
carnitine palmitoyltransferase 2 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of CPT2 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095
|
|
G |
Cpz |
carboxypeptidase Z |
increases expression |
EXP |
Sodium Glutamate results in increased expression of CPZ mRNA |
CTD |
PMID:20928830 |
|
NCBI chr14:75,223,692...75,246,946
Ensembl chr14:75,223,605...75,246,945
|
|
G |
Crat |
carnitine O-acetyltransferase |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of CRAT mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 3:13,675,684...13,689,282
Ensembl chr 3:13,675,684...13,689,255
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions increases expression affects expression decreases phosphorylation |
ISO EXP |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CREB1 mRNA 6-methyl-2-(phenylethynyl)pyridine inhibits the reaction [Sodium Glutamate results in increased expression of CREB1 mRNA]; Dizocilpine Maleate inhibits the reaction [Sodium Glutamate results in increased expression of CREB1 mRNA] Sodium Glutamate affects the expression of CREB1 mRNA Sodium Glutamate results in decreased phosphorylation of CREB1 protein |
CTD |
PMID:23783067 PMID:28954212 PMID:31981724 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crebbp |
CREB binding protein |
decreases expression |
EXP |
Sodium Glutamate results in decreased expression of CREBBP mRNA |
CTD |
PMID:28954212 |
|
NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888
|
|
G |
Creld2 |
cysteine-rich with EGF-like domains 2 |
multiple interactions decreases expression |
ISO |
[Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of CRELD2 mRNA Sodium Glutamate results in decreased expression of CRELD2 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 7:119,909,626...119,916,556
Ensembl chr 7:119,909,633...119,916,543
|
|
G |
Crh |
corticotropin releasing hormone |
decreases expression |
EXP |
Sodium Glutamate results in decreased expression of CRH mRNA |
CTD |
PMID:8071649 |
|
NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919
|
|
G |
Crtam |
cytotoxic and regulatory T cell molecule |
increases expression |
ISO |
Sodium Glutamate results in increased expression of CRTAM mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 8:41,340,117...41,377,343
Ensembl chr 8:41,340,837...41,377,343
|
|
G |
Crtap |
cartilage associated protein |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of CRTAP mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 8:114,047,929...114,067,648
Ensembl chr 8:114,047,933...114,067,631
|
|
G |
Cry1 |
cryptochrome circadian regulator 1 |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of CRY1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 7:18,529,823...18,594,092
Ensembl chr 7:18,529,823...18,594,091
|
|
G |
Crybg1 |
crystallin beta-gamma domain containing 1 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of CRYBG1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr20:47,425,030...47,496,918
Ensembl chr20:47,426,183...47,621,392
|
|
G |
Csf1 |
colony stimulating factor 1 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CSF1 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704
|
|
G |
Csf2rb |
colony stimulating factor 2 receptor subunit beta |
multiple interactions |
ISO |
[EPO protein co-treated with Sodium Glutamate] affects the expression of CSF2RB mRNA |
CTD |
PMID:30837834 |
|
NCBI chr 7:109,876,919...109,901,589
Ensembl chr 7:109,886,425...109,904,157
|
|
G |
Ctrb1 |
chymotrypsinogen B1 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of CTRB1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr19:39,652,931...39,657,666
Ensembl chr19:39,652,933...39,657,688
|
|
G |
Cx3cr1 |
C-X3-C motif chemokine receptor 1 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of CX3CR1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 8:119,785,726...119,799,431
Ensembl chr 8:119,782,595...119,800,014
|
|
G |
Cxcl9 |
C-X-C motif chemokine ligand 9 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of CXCL9 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr14:15,722,868...15,727,779
Ensembl chr14:15,722,908...15,728,435
|
|
G |
Cyb5b |
cytochrome b5 type B |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of CYB5B mRNA |
CTD |
PMID:19001666 |
|
NCBI chr19:35,062,871...35,096,741
Ensembl chr19:35,062,813...35,098,249
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with gallocatechol co-treated with Catechin co-treated with epigallocatechin gallate co-treated with epicatechin gallate co-treated with gallocatechol co-treated with gallocatechin gallate] affects the expression of CYP1A2 mRNA; [Sodium Glutamate co-treated with Tea] affects the expression of CYP1A2 mRNA |
CTD |
PMID:25663641 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp20a1 |
cytochrome P450, family 20, subfamily a, polypeptide 1 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of CYP20A1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 9:61,755,804...61,805,123
Ensembl chr 9:61,755,790...61,805,123
|
|
G |
Cyp2a1 |
cytochrome P450, family 2, subfamily a, polypeptide 1 |
multiple interactions |
EXP |
Sodium Glutamate results in increased expression of and results in increased activity of CYP2A1 protein |
CTD |
PMID:7476908 |
|
NCBI chr 1:82,231,611...82,244,887
Ensembl chr 1:82,231,611...82,244,887
|
|
G |
Cyp2a2 |
cytochrome P450, family 2, subfamily a, polypeptide 2 |
multiple interactions |
EXP |
Sodium Glutamate results in decreased expression of and results in decreased activity of CYP2A2 protein |
CTD |
PMID:7476908 |
|
NCBI chr 1:82,263,833...82,289,487
Ensembl chr 1:82,263,833...82,289,487
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
increases expression multiple interactions |
ISO |
Sodium Glutamate results in increased expression of CYP2B10 mRNA [Sodium Glutamate co-treated with gallocatechol co-treated with Catechin co-treated with epigallocatechin gallate co-treated with epicatechin gallate co-treated with gallocatechol co-treated with gallocatechin gallate] affects the expression of CYP2B10 mRNA; [Sodium Glutamate co-treated with High Fructose Corn Syrup] results in increased expression of CYP2B10 mRNA; [Sodium Glutamate co-treated with Tea] affects the expression of CYP2B10 mRNA; [Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of CYP2B10 mRNA |
CTD |
PMID:19001666 PMID:20111022 PMID:25663641 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
increases expression multiple interactions |
ISO |
Sodium Glutamate results in increased expression of CYP2B9 mRNA [Sodium Glutamate co-treated with High Fructose Corn Syrup] results in increased expression of CYP2B9 mRNA; [Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of CYP2B9 mRNA |
CTD |
PMID:19001666 PMID:20111022 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
decreases expression increases expression multiple interactions decreases activity |
EXP |
Sodium Glutamate results in decreased expression of CYP2C11 mRNA Sodium Glutamate results in increased expression of CYP2C11 mRNA; Sodium Glutamate results in increased expression of CYP2C11 mRNA alternative form; Sodium Glutamate results in increased expression of CYP2C11 protein [Sodium Glutamate co-treated with GH1 protein] results in decreased splicing of CYP2C11 mRNA; [Sodium Glutamate co-treated with GH1 protein] results in increased splicing of CYP2C11 mRNA; [Sodium Glutamate co-treated with GH1 protein] results in increased ubiquitination of CYP2C11 protein; GH1 protein affects the reaction [Sodium Glutamate results in decreased activity of CYP2C11 protein]; GH1 protein affects the reaction [Sodium Glutamate results in decreased expression of CYP2C11 mRNA]; GH1 protein inhibits the reaction [Sodium Glutamate results in decreased activity of CYP2C11 protein]; Sodium Glutamate inhibits the reaction [GH1 protein results in increased expression of CYP2C11 protein]; Sodium Glutamate results in increased expression of and affects the splicing of CYP2C11 mRNA alternative form; Sodium Glutamate results in increased expression of and results in decreased splicing of CYP2C11 mRNA; Sodium Glutamate results in increased expression of and results in increased activity of CYP2C11 protein |
CTD |
PMID:7476908 PMID:7965769 PMID:8496838 PMID:11089541 PMID:25697375 |
|
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp2c12 |
cytochrome P450, family 2, subfamily c, polypeptide 12 |
increases expression |
EXP |
Sodium Glutamate results in increased expression of CYP2C12 mRNA; Sodium Glutamate results in increased expression of CYP2C12 protein |
CTD |
PMID:8010984 |
|
NCBI chr 1:238,699,859...238,757,011
Ensembl chr 1:238,699,854...238,757,019
|
|
G |
Cyp2c24 |
cytochrome P450, family 2, subfamily c, polypeptide 24 |
increases expression multiple interactions |
ISO |
Sodium Glutamate results in increased expression of CYP2C55 mRNA [Sodium Glutamate co-treated with High Fructose Corn Syrup] results in increased expression of CYP2C55 mRNA |
CTD |
PMID:19001666 PMID:20111022 |
|
NCBI chr 1:236,873,967...236,936,238
Ensembl chr 1:236,873,967...236,936,238
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
increases expression multiple interactions |
ISO |
Sodium Glutamate results in increased expression of CYP2C29 mRNA [Sodium Glutamate co-treated with gallocatechol co-treated with Catechin co-treated with epigallocatechin gallate co-treated with epicatechin gallate co-treated with gallocatechol co-treated with gallocatechin gallate] affects the expression of CYP2C29 mRNA |
CTD |
PMID:20111022 PMID:25663641 |
|
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with gallocatechol co-treated with Catechin co-treated with epigallocatechin gallate co-treated with epicatechin gallate co-treated with gallocatechol co-treated with gallocatechin gallate] affects the expression of CYP2D22 mRNA; [Sodium Glutamate co-treated with Tea] affects the expression of CYP2D22 mRNA |
CTD |
PMID:25663641 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with gallocatechol co-treated with Catechin co-treated with epigallocatechin gallate co-treated with epicatechin gallate co-treated with gallocatechol co-treated with gallocatechin gallate] affects the expression of CYP2E1 mRNA; [Sodium Glutamate co-treated with Tea] affects the expression of CYP2E1 mRNA |
CTD |
PMID:25663641 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
EXP |
GH1 protein inhibits the reaction [Sodium Glutamate results in decreased expression of and results in decreased activity of CYP3A2 protein]; Sodium Glutamate results in decreased expression of and results in decreased activity of CYP3A2 protein |
CTD |
PMID:7476908 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
decreases expression multiple interactions |
EXP ISO |
Sodium Glutamate results in decreased expression of CYP3A9 mRNA [Sodium Glutamate co-treated with gallocatechol co-treated with Catechin co-treated with epigallocatechin gallate co-treated with epicatechin gallate co-treated with gallocatechol co-treated with gallocatechin gallate] affects the expression of CYP3A13 mRNA; [Sodium Glutamate co-treated with Tea] affects the expression of CYP3A13 mRNA |
CTD |
PMID:20928830 PMID:25663641 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Cyp46a1 |
cytochrome P450, family 46, subfamily a, polypeptide 1 |
increases expression multiple interactions |
ISO EXP |
Sodium Glutamate results in increased expression of CYP46A1 mRNA; Sodium Glutamate results in increased expression of CYP46A1 protein 6-methyl-2-(phenylethynyl)pyridine inhibits the reaction [Sodium Glutamate results in increased expression of CYP46A1 mRNA]; Dizocilpine Maleate inhibits the reaction [Sodium Glutamate results in increased expression of CYP46A1 mRNA]; Dizocilpine Maleate inhibits the reaction [Sodium Glutamate results in increased expression of CYP46A1 protein] |
CTD |
PMID:31981724 |
|
NCBI chr 6:127,243,315...127,274,765
Ensembl chr 6:127,243,315...127,274,760
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions increases expression |
ISO |
[Sodium Glutamate co-treated with High Fructose Corn Syrup] results in increased expression of CYP7A1 mRNA Sodium Glutamate results in increased expression of CYP7A1 mRNA |
CTD |
PMID:19001666 PMID:20111022 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Dbndd1 |
dysbindin domain containing 1 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of DBNDD1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr19:51,539,154...51,548,441
Ensembl chr19:51,539,148...51,548,444
|
|
G |
Dctn1 |
dynactin subunit 1 |
increases expression |
EXP |
Sodium Glutamate results in increased expression of DCTN1 mRNA |
CTD |
PMID:20928830 |
|
NCBI chr 4:115,671,024...115,703,824
Ensembl chr 4:115,661,638...115,703,815
|
|
G |
Dcxr |
dicarbonyl and L-xylulose reductase |
increases expression |
ISO |
Sodium Glutamate results in increased expression of DCXR mRNA |
CTD |
PMID:22078008 |
|
NCBI chr10:106,006,404...106,008,294
|
|
G |
Ddx19b |
DEAD-box helicase 19B |
increases expression |
ISO |
Sodium Glutamate results in increased expression of DDX19B mRNA |
CTD |
PMID:22078008 |
|
NCBI chr19:38,968,215...38,998,907
Ensembl chr19:38,968,215...38,997,259
|
|
G |
Defb1 |
defensin beta 1 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of DEFB1 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr16:70,298,862...70,313,604
Ensembl chr16:70,298,863...70,313,604
|
|
G |
Depdc1b |
DEP domain containing 1B |
multiple interactions |
ISO |
[Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of DEPDC1B mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 2:39,891,163...39,963,779
Ensembl chr 2:39,891,481...39,963,779
|
|
G |
Dglucy |
D-glutamate cyclase |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of DGLUCY mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 6:120,055,480...120,130,910
Ensembl chr 6:120,055,460...120,130,910
|
|
G |
Diablo |
diablo, IAP-binding mitochondrial protein |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of DIABLO mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of DIABLO mRNA |
CTD |
PMID:23783067 |
|
NCBI chr12:33,055,784...33,070,400
Ensembl chr12:33,055,263...33,070,387
|
|
G |
Dlk1 |
delta like non-canonical Notch ligand 1 |
decreases expression |
EXP |
Sodium Glutamate results in decreased expression of DLK1 mRNA |
CTD |
PMID:28954212 |
|
NCBI chr 6:128,410,216...128,417,518
Ensembl chr 6:128,410,316...128,417,522
|
|
G |
Dlx5 |
distal-less homeobox 5 |
increases expression |
EXP |
Sodium Glutamate results in increased expression of DLX5 mRNA |
CTD |
PMID:20928830 |
|
NCBI chr 4:34,999,139...35,003,504
Ensembl chr 4:34,999,139...35,003,407
|
|
G |
Dnaja1 |
DnaJ heat shock protein family (Hsp40) member A1 |
decreases expression multiple interactions |
ISO |
Sodium Glutamate results in decreased expression of DNAJA1 mRNA [Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of DNAJA1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 5:55,842,414...55,853,326
Ensembl chr 5:55,842,426...55,853,967
|
|
G |
Dnajc27 |
DnaJ heat shock protein family (Hsp40) member C27 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of DNAJC27 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of DNAJC27 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr 6:27,068,713...27,098,449
Ensembl chr 6:27,068,686...27,098,449
|
|
G |
Dnal1 |
dynein, axonemal, light chain 1 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of DNAL1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 6:103,747,801...103,779,015
Ensembl chr 6:103,747,753...103,778,878
|
|
G |
Dolpp1 |
dolichyldiphosphatase 1 |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of DOLPP1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 3:13,664,893...13,674,312
Ensembl chr 3:13,665,823...13,674,311
|
|
G |
Dpys |
dihydropyrimidinase |
increases expression |
ISO |
Sodium Glutamate results in increased expression of DPYS mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 7:70,822,648...70,929,255
Ensembl chr 7:70,835,789...70,929,231
|
|
G |
Dsp |
desmoplakin |
increases expression multiple interactions |
ISO |
Sodium Glutamate results in increased expression of DSP mRNA [Sodium Glutamate co-treated with Trans Fatty Acids] results in decreased expression of DSP mRNA |
CTD |
PMID:19001666 |
|
NCBI chr17:26,623,602...26,671,692
Ensembl chr17:26,623,588...26,671,800
|
|
G |
Duox2 |
dual oxidase 2 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of DUOX2 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 3:109,223,809...109,247,023
Ensembl chr 3:109,226,924...109,245,902
|
|
G |
Dynlt3 |
dynein light chain Tctex-type 3 |
multiple interactions |
ISO |
[Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of DYNLT3 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr X:13,327,933...13,337,139
Ensembl chr X:13,327,892...13,337,139
|
|
G |
Dzip1 |
DAZ interacting zinc finger protein 1 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of DZIP1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr15:95,956,329...96,009,994
Ensembl chr15:95,956,398...96,010,066
|
|
G |
E2f1 |
E2F transcription factor 1 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of E2F1 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of E2F1 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361
|
|
G |
E2f3 |
E2F transcription factor 3 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of E2F3 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr17:34,601,756...34,679,139
Ensembl chr17:34,601,830...34,676,253
|
|
G |
Ecel1 |
endothelin converting enzyme-like 1 |
increases expression |
EXP |
Sodium Glutamate results in increased expression of ECEL1 mRNA |
CTD |
PMID:20928830 |
|
NCBI chr 9:87,814,434...87,829,154
Ensembl chr 9:87,816,718...87,826,675
|
|
G |
Ech1 |
enoyl-CoA hydratase 1 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with High Fructose Corn Syrup] results in increased expression of ECH1 mRNA |
CTD |
PMID:20111022 |
|
NCBI chr 1:84,114,494...84,120,788
Ensembl chr 1:84,112,751...84,120,795
|
|
G |
Efna1 |
ephrin A1 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of EFNA1 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 2:174,681,676...174,690,306
Ensembl chr 2:174,681,682...174,690,866
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions decreases expression |
ISO EXP |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in decreased expression of EGFR mRNA Sodium Glutamate results in decreased expression of EGFR mRNA |
CTD |
PMID:19001666 PMID:28954212 |
|
NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Ehhadh |
enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of EHHADH mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of EHHADH mRNA; [Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of EHHADH mRNA |
CTD |
PMID:19001666 PMID:23783067 |
|
NCBI chr11:79,241,927...79,275,173
Ensembl chr11:79,241,938...79,275,188
|
|
G |
Eif2ak4 |
eukaryotic translation initiation factor 2 alpha kinase 4 |
multiple interactions increases expression |
ISO |
[Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of EIF2AK4 mRNA Sodium Glutamate results in increased expression of EIF2AK4 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 3:105,356,261...105,441,630
Ensembl chr 3:105,356,261...105,441,630
|
|
G |
Eif4ebp2 |
eukaryotic translation initiation factor 4E binding protein 2 |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of EIF4EBP2 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr20:29,379,444...29,400,131
Ensembl chr20:29,382,668...29,399,946
|
|
G |
Elane |
elastase, neutrophil expressed |
increases expression |
ISO |
Sodium Glutamate results in increased expression of ELANE mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 7:9,817,251...9,819,174
Ensembl chr 7:9,817,252...9,819,100
|
|
G |
Elmo3 |
engulfment and cell motility 3 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of ELMO3 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr19:33,181,952...33,186,399
Ensembl chr19:33,182,036...33,186,410
|
|
G |
Elovl6 |
ELOVL fatty acid elongase 6 |
multiple interactions |
ISO |
3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine affects the reaction [[Dietary Fats co-treated with Sodium Glutamate] affects the expression of ELOVL6 mRNA]; [Dietary Fats co-treated with Sodium Glutamate] affects the expression of ELOVL6 mRNA |
CTD |
PMID:26670228 |
|
NCBI chr 2:218,063,682...218,174,767
Ensembl chr 2:218,063,804...218,171,186
|
|
G |
Emilin1 |
elastin microfibril interfacer 1 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of EMILIN1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 6:25,455,974...25,463,736
Ensembl chr 6:25,445,298...25,463,698
|
|
G |
Emp1 |
epithelial membrane protein 1 |
decreases expression multiple interactions |
ISO |
Sodium Glutamate results in decreased expression of EMP1 mRNA [Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of EMP1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 4:168,212,901...168,233,039
Ensembl chr 4:168,212,861...168,232,904
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of EPHX2 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of EPHX2 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615
|
|
G |
Epo |
erythropoietin |
multiple interactions increases expression affects expression |
ISO EXP |
[EPO protein co-treated with Sodium Glutamate] affects the expression of CSF2RB mRNA; [EPO protein co-treated with Sodium Glutamate] results in increased expression of EPO protein; [EPO protein co-treated with Sodium Glutamate] results in increased expression of EPOR mRNA; [EPO protein co-treated with Sodium Glutamate] results in increased expression of EPOR protein; EPO protein inhibits the reaction [Sodium Glutamate results in increased expression of EPO mRNA] Sodium Glutamate affects the expression of EPO protein |
CTD |
PMID:30837834 |
|
NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946
|
|
G |
Epor |
erythropoietin receptor |
increases expression multiple interactions |
EXP ISO |
Sodium Glutamate results in increased expression of EPOR protein [EPO protein co-treated with Sodium Glutamate] results in increased expression of EPOR mRNA; [EPO protein co-treated with Sodium Glutamate] results in increased expression of EPOR protein |
CTD |
PMID:30837834 |
|
NCBI chr 8:20,489,678...20,494,257
Ensembl chr 8:20,489,678...20,494,257
|
|
G |
Erbb3 |
erb-b2 receptor tyrosine kinase 3 |
increases expression multiple interactions |
ISO |
Sodium Glutamate results in increased expression of ERBB3 mRNA [Sodium Glutamate co-treated with Trans Fatty Acids] results in decreased expression of ERBB3 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 7:994,549...1,015,876
Ensembl chr 7:996,225...1,015,525
|
|
G |
Erlin1 |
ER lipid raft associated 1 |
multiple interactions |
ISO |
[Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of ERLIN1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 1:242,921,147...242,956,472
Ensembl chr 1:242,921,152...242,956,394
|
|
G |
Esrrb |
estrogen-related receptor beta |
increases expression |
ISO |
Sodium Glutamate results in increased expression of ESRRB mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 6:106,007,662...106,163,136
Ensembl chr 6:106,008,095...106,160,791
|
|
G |
Exosc8 |
exosome component 8 |
multiple interactions |
ISO |
[Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of EXOSC8 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 2:138,930,405...138,937,009
Ensembl chr 2:138,930,405...138,936,928
|
|
G |
Ezh1 |
enhancer of zeste 1 polycomb repressive complex 2 subunit |
multiple interactions |
ISO |
[Trans Fatty Acids co-treated with Sodium Glutamate] results in decreased expression of EZH1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr10:86,126,023...86,162,001
Ensembl chr10:86,126,015...86,161,921
|
|
G |
Faap24 |
FA core complex associated protein 24 |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of FAAP24 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 1:88,051,523...88,057,997
Ensembl chr 1:88,051,911...88,057,989
|
|
G |
Fabp5 |
fatty acid binding protein 5 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of FABP5 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 2:91,765,056...91,768,716
Ensembl chr 2:91,765,056...91,853,773
|
|
G |
Fads1 |
fatty acid desaturase 1 |
multiple interactions increases expression |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of FADS1 mRNA Sodium Glutamate results in increased expression of FADS1 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 1:206,827,724...206,842,734
Ensembl chr 1:206,827,765...206,842,734
|
|
G |
Fads2 |
fatty acid desaturase 2 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of FADS2 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789
|
|
G |
Faim |
Fas apoptotic inhibitory molecule |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with High Fructose Corn Syrup] results in increased expression of FAIM mRNA |
CTD |
PMID:20111022 |
|
NCBI chr 8:99,543,877...99,569,499
Ensembl chr 8:99,542,405...99,560,562
|
|
G |
Faim2 |
Fas apoptotic inhibitory molecule 2 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of FAIM2 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 7:130,632,368...130,659,353
Ensembl chr 7:130,633,348...130,659,168
|
|
G |
Fam78b |
family with sequence similarity 78, member B |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of FAM78B mRNA |
CTD |
PMID:22078008 |
|
NCBI chr13:79,162,405...79,250,958
Ensembl chr13:79,162,228...79,250,500
|
|
G |
Fan1 |
FANCD2 and FANCI associated nuclease 1 |
affects methylation |
EXP |
Sodium Glutamate affects the methylation of FAN1 gene |
CTD |
PMID:29381301 |
|
NCBI chr 1:117,915,323...117,945,044
Ensembl chr 1:117,917,099...117,944,977
|
|
G |
Faslg |
Fas ligand |
increases expression multiple interactions |
ISO |
Sodium Glutamate results in increased expression of FASL mRNA SB 203580 inhibits the reaction [Sodium Glutamate results in increased expression of FASL mRNA] |
CTD |
PMID:16782274 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fasn |
fatty acid synthase |
increases expression multiple interactions |
EXP ISO |
Sodium Glutamate results in increased expression of FASN mRNA [Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of FASN mRNA; fructooligosaccharide inhibits the reaction [Sodium Glutamate results in increased expression of FASN mRNA]; SRT1720 inhibits the reaction [Sodium Glutamate results in increased expression of FASN mRNA]; SRT1720 inhibits the reaction [Sodium Glutamate results in increased expression of FASN protein] Sodium Glutamate results in increased expression of FASN mRNA; Sodium Glutamate results in increased expression of FASN protein |
CTD |
PMID:19001666 PMID:19724016 PMID:26092479 PMID:32103741 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fat3 |
FAT atypical cadherin 3 |
decreases expression |
EXP |
Sodium Glutamate results in decreased expression of FAT3 mRNA |
CTD |
PMID:20928830 |
|
NCBI chr 8:12,691,470...13,274,336
Ensembl chr 8:12,694,019...13,273,135
|
|
G |
Fbln1 |
fibulin 1 |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of FBLN1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 7:116,310,582...116,390,075
Ensembl chr 7:116,310,582...116,390,075
|
|
G |
Fbn2 |
fibrillin 2 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of FBN2 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr18:51,499,737...51,703,976
Ensembl chr18:51,499,737...51,703,976
|
|
G |
Fbxo15 |
F-box protein 15 |
affects methylation |
EXP |
Sodium Glutamate affects the methylation of FBXO15 gene |
CTD |
PMID:29381301 |
|
NCBI chr18:78,296,999...78,634,695
Ensembl chr18:78,319,534...78,390,765
|
|
G |
Fbxo41 |
F-box protein 41 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of FBXO41 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 4:118,007,517...118,039,547
Ensembl chr 4:118,010,978...118,039,406
|
|
G |
Fdps |
farnesyl diphosphate synthase |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of FDPS mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 2:174,497,402...174,507,031
Ensembl chr 2:174,486,665...174,507,776
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of FGF2 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fgf21 |
fibroblast growth factor 21 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of FGF21 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 1:96,083,495...96,084,738
Ensembl chr 1:96,083,441...96,090,454
|
|
G |
Fgf8 |
fibroblast growth factor 8 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of FGF8 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 1:244,584,477...244,590,359
Ensembl chr 1:244,584,652...244,590,359
|
|
G |
Fgfr2 |
fibroblast growth factor receptor 2 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of FGFR2 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 1:184,745,418...184,850,655
Ensembl chr 1:184,745,420...184,850,626
|
|
G |
Flt1 |
Fms related receptor tyrosine kinase 1 |
decreases expression |
EXP |
Sodium Glutamate results in decreased expression of FLT1 protein |
CTD |
PMID:28755050 |
|
NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626
|
|
G |
Fmo2 |
flavin containing dimethylaniline monoxygenase 2 |
increases expression multiple interactions |
ISO |
Sodium Glutamate results in increased expression of FMO2 mRNA [Sodium Glutamate co-treated with High Fructose Corn Syrup] results in increased expression of FMO2 mRNA; [Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of FMO2 mRNA |
CTD |
PMID:19001666 PMID:20111022 |
|
NCBI chr13:75,221,149...75,244,377
Ensembl chr13:75,224,402...75,244,308
|
|
G |
Fmod |
fibromodulin |
increases expression |
ISO |
Sodium Glutamate results in increased expression of FMOD mRNA |
CTD |
PMID:19001666 |
|
NCBI chr13:45,493,517...45,504,134
Ensembl chr13:45,493,517...45,504,133
|
|
G |
Folr2 |
folate receptor beta |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of FOLR2 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 1:156,200,044...156,218,380
Ensembl chr 1:156,200,060...156,205,724
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
decreases expression |
EXP |
Sodium Glutamate results in decreased expression of FOS mRNA |
CTD |
PMID:28954212 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Foxb2 |
forkhead box B2 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of FOXB2 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 1:214,232,731...214,234,226
Ensembl chr 1:214,232,731...214,234,226
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of FOXO3 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
|
|
G |
Foxp4 |
forkhead box P4 |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of FOXP4 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 9:13,058,506...13,115,406
Ensembl chr 9:13,058,476...13,114,879
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
decreases secretion |
ISO |
Sodium Glutamate results in decreased secretion of FSHB protein |
CTD |
PMID:30733785 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Ftcd |
formimidoyltransferase cyclodeaminase |
increases expression |
ISO |
Sodium Glutamate results in increased expression of FTCD mRNA |
CTD |
PMID:22078008 |
|
NCBI chr20:12,055,203...12,068,717
Ensembl chr20:12,055,208...12,068,735
|
|
G |
Fxyd6 |
FXYD domain-containing ion transport regulator 6 |
multiple interactions |
ISO |
[Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of FXYD6 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 8:45,679,054...45,705,958
Ensembl chr 8:45,678,885...45,705,958
|
|
G |
G0s2 |
G0/G1switch 2 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with High Fructose Corn Syrup] results in increased expression of G0S2 mRNA |
CTD |
PMID:20111022 |
|
NCBI chr13:104,806,351...104,807,263
Ensembl chr13:104,806,156...104,807,451
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of G6PDX mRNA |
CTD |
PMID:19001666 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gad1 |
glutamate decarboxylase 1 |
decreases expression increases expression |
EXP |
Sodium Glutamate results in decreased expression of GAD1 mRNA Sodium Glutamate results in increased expression of GAD1 protein |
CTD |
PMID:19733649 |
|
NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:55,369,704...55,410,333
|
|
G |
Gad2 |
glutamate decarboxylase 2 |
increases expression decreases expression affects expression |
EXP |
Sodium Glutamate results in increased expression of GAD2 mRNA Sodium Glutamate results in decreased expression of GAD2 protein Sodium Glutamate affects the expression of GAD2 protein |
CTD |
PMID:19733649 |
|
NCBI chr17:84,763,630...84,826,155
Ensembl chr17:84,763,628...84,826,155
|
|
G |
Gadd45b |
growth arrest and DNA-damage-inducible, beta |
increases expression multiple interactions |
ISO |
Sodium Glutamate results in increased expression of GADD45B mRNA [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of GADD45B mRNA; [Sodium Glutamate co-treated with High Fructose Corn Syrup] results in increased expression of GADD45B mRNA |
CTD |
PMID:19001666 PMID:20111022 PMID:23783067 |
|
NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046
|
|
G |
Gale |
UDP-galactose-4-epimerase |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of GALE mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 5:148,193,886...148,198,392
Ensembl chr 5:148,194,791...148,198,388
|
|
G |
Galk1 |
galactokinase 1 |
multiple interactions increases expression |
ISO |
[Sodium Glutamate co-treated with High Fructose Corn Syrup] results in increased expression of GALK1 mRNA; [Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of GALK1 mRNA Sodium Glutamate results in increased expression of GALK1 mRNA |
CTD |
PMID:19001666 PMID:20111022 |
|
NCBI chr10:101,243,146...101,247,323
Ensembl chr10:101,235,994...101,247,337
|
|
G |
Galnt10 |
polypeptide N-acetylgalactosaminyltransferase 10 |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of GALNT10 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr10:41,821,216...41,967,618
Ensembl chr10:41,820,158...41,967,013
|
|
G |
Galp |
galanin-like peptide |
increases expression |
ISO |
Sodium Glutamate results in increased expression of GALP mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 1:67,684,023...67,703,121
Ensembl chr 1:67,684,025...67,702,269
|
|
G |
Gas2l1 |
growth arrest-specific 2 like 1 |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of GAS2L1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr14:79,951,702...79,961,830
Ensembl chr14:79,950,555...79,961,438
|
|
G |
Gbe1 |
1,4-alpha-glucan branching enzyme 1 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of GBE1 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr11:8,734,806...9,000,226
Ensembl chr11:8,734,820...9,000,210
|
|
G |
Gdpd5 |
glycerophosphodiester phosphodiesterase domain containing 5 |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of GDPD5 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 1:153,679,718...153,761,452
Ensembl chr 1:153,679,718...153,761,446
|
|
G |
Gfap |
glial fibrillary acidic protein |
increases expression |
EXP |
Sodium Glutamate results in increased expression of GFAP mRNA |
CTD |
PMID:20928830 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Gfm2 |
GTP dependent ribosome recycling factor mitochondrial 2 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of GFM2 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of GFM2 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr 2:28,449,452...28,488,200
Ensembl chr 2:28,449,517...28,488,197
|
|
G |
Gfod2 |
glucose-fructose oxidoreductase domain containing 2 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of GFOD2 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr19:33,599,689...33,647,060
Ensembl chr19:33,604,187...33,647,004
|
|
G |
Gh1 |
growth hormone 1 |
decreases secretion multiple interactions affects expression decreases expression |
EXP |
Sodium Glutamate results in decreased secretion of GH1 protein [Octreotide co-treated with Sodium Glutamate] results in decreased expression of and results in decreased secretion of GH1 protein; [Sodium Glutamate co-treated with GH1 protein] results in decreased splicing of CYP2C11 mRNA; [Sodium Glutamate co-treated with GH1 protein] results in increased splicing of CYP2C11 mRNA; [Sodium Glutamate co-treated with GH1 protein] results in increased ubiquitination of CYP2C11 protein; GH1 protein affects the reaction [Sodium Glutamate results in decreased activity of CYP2C11 protein]; GH1 protein affects the reaction [Sodium Glutamate results in decreased expression of CYP2C11 mRNA]; GH1 protein inhibits the reaction [Sodium Glutamate results in decreased activity of CYP2C11 protein]; GH1 protein inhibits the reaction [Sodium Glutamate results in decreased expression of and results in decreased activity of CYP3A2 protein]; GH1 protein inhibits the reaction [Sodium Glutamate results in decreased expression of IGF1 mRNA]; GH1 protein inhibits the reaction [Sodium Glutamate results in increased expression of IGF1R mRNA]; GHRH protein affects the reaction [Sodium Glutamate results in decreased expression of GH1 mRNA]; JI-38 inhibits the reaction [Sodium Glutamate results in decreased secretion of GH1 protein]; Sodium Glutamate inhibits the reaction [GH1 protein results in decreased expression of SOCS2 mRNA]; Sodium Glutamate inhibits the reaction [GH1 protein results in increased expression of CYP2C11 protein]; Sodium Glutamate inhibits the reaction [GH1 protein results in increased expression of GHR mRNA]; Sodium Glutamate inhibits the reaction [GH1 protein results in increased expression of GHR protein]; Sodium Glutamate inhibits the reaction [GH1 protein results in increased expression of SOCS2 mRNA]; Sodium Glutamate inhibits the reaction [GH1 protein results in increased expression of SOCS2 protein]; Sodium Glutamate inhibits the reaction [GHRL protein results in increased secretion of GH1 protein]; Sodium Glutamate results in decreased expression of and results in decreased secretion of GH1 protein Sodium Glutamate affects the expression of GH1 protein Sodium Glutamate results in decreased expression of GH1 mRNA; Sodium Glutamate results in decreased expression of GH1 protein |
CTD |
PMID:7476908 PMID:7711889 PMID:8368293 PMID:8496838 PMID:9053782 PMID:10718930 PMID:12193538 PMID:25697375 More...
|
|
NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078
|
|
G |
Ghdc |
GH3 domain containing |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of GHDC mRNA |
CTD |
PMID:22078008 |
|
NCBI chr10:85,693,612...85,697,833
Ensembl chr10:85,693,616...85,697,865
|
|
G |
Ghr |
growth hormone receptor |
multiple interactions increases expression |
EXP |
Sodium Glutamate inhibits the reaction [GH1 protein results in increased expression of GHR mRNA]; Sodium Glutamate inhibits the reaction [GH1 protein results in increased expression of GHR protein] Sodium Glutamate results in increased expression of GHR mRNA; Sodium Glutamate results in increased expression of GHR protein |
CTD |
PMID:25697375 |
|
NCBI chr 2:52,541,452...52,804,960
Ensembl chr 2:52,542,594...52,804,735
|
|
G |
Ghrh |
growth hormone releasing hormone |
multiple interactions decreases expression |
EXP |
[Sodium Glutamate co-treated with Octreotide] results in decreased expression of GHRH mRNA; GHRH protein affects the reaction [Sodium Glutamate results in decreased expression of GH1 mRNA] Sodium Glutamate results in decreased expression of GHRH mRNA |
CTD |
PMID:2004597 PMID:8368293 PMID:9053782 |
|
NCBI chr 3:145,992,762...146,012,528
Ensembl chr 3:145,992,763...146,011,889
|
|
G |
Ghrhr |
growth hormone releasing hormone receptor |
increases expression |
EXP |
Sodium Glutamate results in increased expression of GHRHR mRNA |
CTD |
PMID:10718930 |
|
NCBI chr 4:84,498,159...84,532,847
Ensembl chr 4:84,500,212...84,532,776
|
|
G |
Ghrl |
ghrelin and obestatin prepropeptide |
multiple interactions |
EXP |
Sodium Glutamate inhibits the reaction [GHRL protein results in increased secretion of GH1 protein] |
CTD |
PMID:12193538 |
|
NCBI chr 4:146,865,712...146,869,621
Ensembl chr 4:146,865,712...146,869,621
|
|
G |
Ghsr |
growth hormone secretagogue receptor |
increases expression |
EXP |
Sodium Glutamate results in increased expression of GHSR mRNA |
CTD |
PMID:10718930 |
|
NCBI chr 2:110,268,489...110,271,865
Ensembl chr 2:110,268,489...110,271,865
|
|
G |
Gigyf1 |
GRB10 interacting GYF protein 1 |
increases expression multiple interactions |
ISO |
Sodium Glutamate results in increased expression of GIGYF1 mRNA [Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of GIGYF1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr12:19,166,070...19,181,570
Ensembl chr12:19,166,088...19,175,023
|
|
G |
Gip |
gastric inhibitory polypeptide |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate] results in increased expression of GIP protein; Sodium Glutamate inhibits the reaction [Aspartame promotes the reaction [Fats, Unsaturated results in increased expression of GIP protein]] |
CTD |
PMID:23783067 |
|
NCBI chr10:80,968,410...80,976,506
Ensembl chr10:80,968,352...80,976,503
|
|
G |
Gk |
glycerol kinase |
multiple interactions increases expression |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in decreased expression of GK mRNA Sodium Glutamate results in increased expression of GK mRNA |
CTD |
PMID:19001666 |
|
NCBI chr X:50,162,089...50,238,707
Ensembl chr X:50,163,123...50,238,631
|
|
G |
Glrx |
glutaredoxin |
increases expression decreases expression multiple interactions |
ISO |
Sodium Glutamate results in increased expression of GLRX mRNA Sodium Glutamate results in decreased expression of GLRX mRNA [Sodium Glutamate co-treated with High Fructose Corn Syrup] results in increased expression of GLRX mRNA |
CTD |
PMID:20111022 PMID:22078008 |
|
NCBI chr 2:5,341,873...5,351,686
Ensembl chr 2:5,341,885...5,351,680
|
|
G |
Glud1 |
glutamate dehydrogenase 1 |
multiple interactions |
EXP |
Sodium Glutamate results in decreased expression of and results in decreased activity of GLUD1 protein |
CTD |
PMID:11807584 |
|
NCBI chr16:9,640,312...9,673,961
Ensembl chr16:9,640,312...9,673,957
|
|
G |
Gmeb2 |
glucocorticoid modulatory element binding protein 2 |
increases expression |
EXP |
Sodium Glutamate results in increased expression of GMEB2 mRNA |
CTD |
PMID:20928830 |
|
NCBI chr 3:168,362,650...168,400,788
Ensembl chr 3:168,362,650...168,400,788
|
|
G |
Gmfb |
glia maturation factor, beta |
multiple interactions |
ISO |
[Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of GMFB mRNA |
CTD |
PMID:22078008 |
|
NCBI chr15:20,069,923...20,081,005
Ensembl chr15:20,067,263...20,080,331
|
|
G |
Gnpat |
glyceronephosphate O-acyltransferase |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of GNPAT mRNA |
CTD |
PMID:19001666 |
|
NCBI chr19:52,822,326...52,848,872
Ensembl chr19:52,822,319...52,852,361
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with High Fructose Corn Syrup] results in decreased expression of GOT1 mRNA |
CTD |
PMID:20111022 |
|
NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633
|
|
G |
Gpat3 |
glycerol-3-phosphate acyltransferase 3 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of GPAT3 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr14:8,715,367...8,768,051
Ensembl chr14:8,714,373...8,766,490
|
|
G |
Gpc2 |
glypican 2 |
increases expression |
EXP |
Sodium Glutamate results in increased expression of GPC2 mRNA |
CTD |
PMID:20928830 |
|
NCBI chr12:17,277,875...17,284,297
Ensembl chr12:17,277,875...17,284,208
|
|
G |
Gpr85 |
G protein-coupled receptor 85 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of GPR85 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 4:42,100,138...42,109,584
Ensembl chr 4:42,102,941...42,109,566
|
|
G |
Gprc5c |
G protein-coupled receptor, class C, group 5, member C |
increases expression |
ISO |
Sodium Glutamate results in increased expression of GPRC5C mRNA |
CTD |
PMID:19001666 |
|
NCBI chr10:99,886,900...99,908,928
Ensembl chr10:99,887,077...99,908,926
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
increases activity increases expression multiple interactions decreases expression |
ISO |
Sodium Glutamate results in increased activity of GPT protein Sodium Glutamate results in increased expression of GPT protein 2-ethoxy-3-(4-(2-(4-trifluoromethanesulfonyloxyphenyl)ethoxy)phenyl)propionic acid promotes the reaction [Sodium Glutamate results in increased activity of GPT protein]; 3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine affects the reaction [[Dietary Fats co-treated with Sodium Glutamate] affects the expression of GPT protein]; [Dietary Fats co-treated with Sodium Glutamate] affects the expression of GPT protein; Bezafibrate promotes the reaction [Sodium Glutamate results in increased expression of GPT protein]; fructooligosaccharide inhibits the reaction [Sodium Glutamate results in increased expression of GPT protein]; Rosiglitazone promotes the reaction [Sodium Glutamate results in increased activity of GPT protein] Sodium Glutamate results in decreased expression of GPT protein |
CTD |
PMID:18048028 PMID:19724016 PMID:21205225 PMID:21549692 PMID:26670228 PMID:32103741 More...
|
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions decreases expression increases expression |
ISO |
SRT1720 inhibits the reaction [Sodium Glutamate results in increased expression of GPX1 mRNA]; SRT1720 inhibits the reaction [Sodium Glutamate results in increased expression of GPX1 protein] Sodium Glutamate results in decreased expression of GPX1 mRNA Sodium Glutamate results in increased expression of GPX1 mRNA; Sodium Glutamate results in increased expression of GPX1 protein |
CTD |
PMID:19724016 PMID:30733785 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
affects expression decreases expression |
ISO |
Sodium Glutamate affects the expression of GPX2 mRNA Sodium Glutamate results in decreased expression of GPX2 protein |
CTD |
PMID:25473020 |
|
NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877
|
|
G |
Gria2 |
glutamate ionotropic receptor AMPA type subunit 2 |
affects expression multiple interactions |
ISO EXP |
Sodium Glutamate affects the expression of GRIA2 protein SB 203580 affects the reaction [Sodium Glutamate affects the expression of GRIA2] |
CTD |
PMID:15139026 PMID:16782274 |
|
NCBI chr 2:165,949,379...166,069,510
Ensembl chr 2:165,947,521...166,069,510
|
|
G |
Grifin |
galectin-related inter-fiber protein |
increases expression |
ISO |
Sodium Glutamate results in increased expression of GRIFIN mRNA |
CTD |
PMID:22078008 |
|
NCBI chr12:14,080,170...14,082,892
Ensembl chr12:14,080,910...14,082,877
|
|
G |
Grik3 |
glutamate ionotropic receptor kainate type subunit 3 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of GRIK3 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 5:137,767,865...137,989,617
Ensembl chr 5:137,767,865...137,984,307
|
|
G |
Grik5 |
glutamate ionotropic receptor kainate type subunit 5 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with High Fructose Corn Syrup] results in increased expression of GRIK5 mRNA |
CTD |
PMID:20111022 |
|
NCBI chr 1:80,605,878...80,667,896
Ensembl chr 1:80,605,892...80,667,125
|
|
G |
Grin1 |
glutamate ionotropic receptor NMDA type subunit 1 |
increases expression |
EXP |
Sodium Glutamate results in increased expression of GRIN1 |
CTD |
PMID:15139026 |
|
NCBI chr 3:8,103,680...8,130,603
Ensembl chr 3:8,103,680...8,130,603
|
|
G |
Grin2c |
glutamate ionotropic receptor NMDA type subunit 2C |
increases expression |
EXP |
Sodium Glutamate results in increased expression of GRIN2C mRNA |
CTD |
PMID:11872244 |
|
NCBI chr10:100,488,430...100,507,083
Ensembl chr10:100,488,431...100,506,427
|
|
G |
Grin2d |
glutamate ionotropic receptor NMDA type subunit 2D |
increases expression decreases expression |
EXP |
Sodium Glutamate results in increased expression of GRIN2D mRNA Sodium Glutamate results in decreased expression of GRIN2D mRNA |
CTD |
PMID:11872244 PMID:20928830 |
|
NCBI chr 1:96,306,871...96,346,994
Ensembl chr 1:96,308,365...96,344,793
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions decreases activity |
ISO |
Sodium Glutamate results in increased expression of and results in decreased activity of GSR protein; Tea inhibits the reaction [Sodium Glutamate results in decreased activity of GSR protein] |
CTD |
PMID:25473020 PMID:29679905 PMID:30733785 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gstm2 |
glutathione S-transferase mu 2 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of GSTM2 mRNA |
CTD |
PMID:20111022 |
|
NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961
|
|
G |
Gstm4 |
glutathione S-transferase mu 4 |
increases expression multiple interactions |
ISO |
Sodium Glutamate results in increased expression of GSTM4 mRNA [Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of GSTM4 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 2:195,667,940...195,685,315
Ensembl chr 2:195,680,004...195,685,323
|
|
G |
Gstm5 |
glutathione S-transferase, mu 5 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of GSTM3 mRNA |
CTD |
PMID:19001666 PMID:25473020 |
|
NCBI chr 2:195,531,627...195,534,562
Ensembl chr 2:195,531,495...195,534,553
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of GSTP1 protein |
CTD |
PMID:29441869 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Gtf2b |
general transcription factor IIB |
increases expression multiple interactions |
ISO |
Sodium Glutamate results in increased expression of GTF2B mRNA [Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of GTF2B mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 2:231,767,317...231,785,626
Ensembl chr 2:231,767,238...231,785,651
|
|
G |
Gtf2h2 |
general transcription factor IIH subunit 2 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of GTF2H2 mRNA |
| |